



University of Dundee

A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn's disease following surgical resection (TOPPIC)

Satsangi, Jack; Kennedy, Nicholas A.; Mowat, Craig; Arnott, Ian; Keerie, Catriona; Lewis, Steff ; Ennis, Holly; on behalf of the TOPPIC Collaborators Group

Published in:
Efficacy and Mechanism Evaluation

DOI:
[10.3310/eme04040](https://doi.org/10.3310/eme04040)

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Satsangi, J., Kennedy, N. A., Mowat, C., Arnott, I., Keerie, C., Lewis, S., ... on behalf of the TOPPIC Collaborators Group (2017). A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn's disease following surgical resection (TOPPIC). *Efficacy and Mechanism Evaluation*, 4(4), 1-59. DOI: 10.3310/eme04040

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn's disease following surgical resection (TOPPIC)

*Jack Satsangi, Nicholas A Kennedy, Craig Mowat, Ian Arnott, Catriona Keerie, Steff Lewis and Holly Ennis
on behalf of the TOPPIC Collaborators Group*



***National Institute for
Health Research***

A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn's disease following surgical resection (TOPPIC)

Jack Satsangi,^{1*} Nicholas A Kennedy,^{1,2,3} Craig Mowat,⁴ Ian Arnott,⁵ Catriona Keerie,⁶ Steff Lewis⁶ and Holly Ennis⁶ on behalf of the TOPPIC Collaborators Group

¹Gastrointestinal Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

²Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, UK

³School of Medicine, University of Exeter, Exeter, UK

⁴Gastrointestinal Unit, Ninewells Hospital, Dundee, UK

⁵Gastrointestinal Unit, Western General Hospital, Edinburgh, UK

⁶Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

*Corresponding author

Declared competing interests of authors: Jack Satsangi reports personal fees from Takeda Pharmaceutical Company Ltd, AbbVie Inc. and Dr Falk Pharma UK Ltd, and research funding from the European Commission. Nicholas A Kennedy reports grants from The Wellcome Trust; personal fees from Merck & Co., Inc., Takeda Pharmaceutical Company Ltd, Dr Falk Pharma UK Ltd, Allergan, plc, and Pharmacosmos A/S; non-financial support from Norgine BV, AbbVie Inc., Shire, plc, and Janssen Global Services, LLC; and other support from Merck & Co., Inc., AbbVie Inc. and Takeda Pharmaceutical Company Ltd outside the submitted work. Ian Arnott reports personal fees from Vifor Pharma Management Ltd, Takeda Pharmaceutical Company Ltd and Dr Falk Pharma UK Ltd. Steff Lewis reports membership of the Health Technology Assessment Efficient Study Designs Board and University of Edinburgh grant funding.

Published September 2017

DOI: 10.3310/eme04040

This report should be referenced as follows:

Satsangi J, Kennedy NA, Mowat C, Arnott I, Keerie C, Lewis S, *et al.* A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn's disease following surgical resection (TOPPIC). *Efficacy Mech Eval* 2017;**4**(4).

Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)

ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the *Efficacy and Mechanism Evaluation* journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting 'science driven' studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: <http://www.nets.nihr.ac.uk/programmes/eme>

This report

The research reported in this issue of the journal was funded by the EME programme as project number 09/800/04. The contractual start date was in October 2007. The final report began editorial review in February 2016 and was accepted for publication in March 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2017. This work was produced by Satsangi *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Efficacy and Mechanism Evaluation Editor-in-Chief

Professor David Crossman Bute Professor of Medicine and Dean and Head of Faculty of Medicine, University of St Andrews, and Honorary Consultant Cardiologist, NHS Fife Health Board, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk

Abstract

A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn's disease following surgical resection (TOPPIC)

Jack Satsangi,^{1*} Nicholas A Kennedy,^{1,2,3} Craig Mowat,⁴ Ian Arnott,⁵ Catriona Keerie,⁶ Steff Lewis⁶ and Holly Ennis⁶ on behalf of the TOPPIC Collaborators Group

¹Gastrointestinal Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

²Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, UK

³School of Medicine, University of Exeter, Exeter, UK

⁴Gastrointestinal Unit, Ninewells Hospital, Dundee, UK

⁵Gastrointestinal Unit, Western General Hospital, Edinburgh, UK

⁶Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

*Corresponding author J.Satsangi@ed.ac.uk

Background: Crohn's disease (CD) is a chronic, relapsing, inflammatory bowel disease. Up to 65% of patients with CD require an operation to control the disease within 10 years. Both endoscopic and clinical recurrence is common within 2 years of operation, with re-operation rates cumulating at 5% of patients per year.

Objectives: This study assessed if the use of mercaptopurine (MP) can prevent or delay postoperative recurrence in CD.

Design: An individually randomised, multicentre, double-blind, placebo-controlled trial with follow-up at 6, 13, 31, 49, 67, 85, 103, 121, 139 and 157 weeks.

Setting: Twenty-nine tertiary referral hospitals in the UK.

Participants: Those aged ≥ 16 years in Scotland (or aged ≥ 18 years in England and Wales) with a histologically confirmed diagnosis of CD (according to the Lennard-Jones criteria) and surgical intervention ≤ 3 months prior to randomisation to remove all observable disease at ileocolonic or small bowel resections. Patients were excluded if they had a known intolerance of or hypersensitivity to thiopurines; were known to require further surgery; underwent strictureplasty alone; had a stoma; or had an active or untreated malignancy or absent thiopurine S-methyltransferase (TPMT) activity. Prior to randomisation any postoperative infections were fully treated and existing treatments for CD were stopped.

Intervention: Daily oral dose of MP or placebo, with dose adjusted according to body weight (kg) and TPMT status. Blood samples for genetic and serological analysis were taken at randomisation with additional blood and stool samples collected at weeks 0, 13, 49, 103 and 157 for central analysis of drug metabolite and faecal calprotectin levels, with endoscopic assessment at weeks 49 and 157.

Main outcome measures: The primary end point was clinical recurrence of CD (Crohn's Disease Activity Index score of > 150 points plus 100-point rise) and the need for anti-inflammatory rescue therapy or

primary surgical intervention. Secondary end points included faecal calprotectin and thioguanine levels, and assessment of endoscopic recurrence. The primary analysis was adjusted for baseline values of previous treatment with MP and azathioprine, with the adjusted analysis considered to be the primary analysis.

Results: Between June 2008 and April 2012, 240 patients were enrolled and received at least one dose of the study drug. A total of 128 (53%) participants were randomised to receive MP and 112 (47%) to receive placebo. No randomised patients were excluded from the analysis. More patients achieved the primary end point in the placebo group ($n = 26$, 23.2%) than in the MP group ($n = 16$, 12.5%), with an adjusted p -value of 0.073 [hazard ratio (HR) 0.535, 95% confidence interval (CI) 0.27 to 1.06]. Of the smokers on MP, 3 out of 29 (10.3%) had clinical recurrence versus 12 out of 26 (46.2%) on placebo, demonstrating that MP was effective at preventing postoperative recurrence in smokers (HR 0.127, 95% CI 0.04 to 0.46) but not in non-smokers (HR 0.898, 95% CI 0.42 to 1.94). The proportion of patients experiencing adverse events was similar in the treatment and placebo groups.

Limitations: There was a lower than anticipated primary event rate (12.5% in the treatment group vs. 23.2% in the placebo group, as opposed to expected rates of 30% vs. 50%).

Conclusions: The Trial Of Prevention of Post operative Crohn's disease (TOPPIC) is the largest single, double-blind trial assessing the use of thiopurines to prevent postoperative recurrence in CD. From the trial itself, MP was not effective in reducing the frequency of clinical postoperative recurrence of CD overall, but the data suggest that it has clinically meaningful effect among the subgroup of patients who continue to smoke after surgery.

Future work: Exploratory analyses of possible predictors of disease recurrence using collected data and samples.

Trial registration: Current Controlled Trials ISRCTN89489788 and EudraCT 2006-005800-15.

Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership, and will be published in full in *Efficacy and Mechanism Evaluation*; Vol. 4, No. 4. See the NIHR Journals Library website for further project information.

Contents

List of tables	ix
List of figures	xi
List of supplementary material	xiii
List of abbreviations	xv
Plain English summary	xvii
Scientific summary	xix
Chapter 1 Introduction	1
Crohn's disease treatment	1
Evidence for postoperative use of thiopurines	1
Current practice	2
Controversies in use of thiopurines in postoperative use	2
The use of thiopurines by women, or the male partners of women, trying to conceive or in pregnancy	2
Potential health-care impact	3
Rationale for research	3
Study aims	3
Development of TOPPIC	3
Chapter 2 Methods	5
Trial design	5
Participants	5
<i>Inclusion criteria</i>	5
<i>Exclusion criteria</i>	5
Identifying participants	6
Settings and locations where the data were collected	6
Interventions	6
Outcomes	6
Measurements	6
Sample processing	7
Therapeutic monitoring	7
Dose changes	7
Sample size	8
Interim analyses and stopping guidelines	9
Randomisation	9
<i>Sequence generation</i>	9
<i>Type of randomisation</i>	9
<i>Implementation</i>	9
<i>Blinding</i>	9
Trial data management	9
Statistical methods	10
Primary outcomes	10
Secondary outcomes	10
Subgroup analyses	11

Publication policy	11
Organisation	11
Confidentiality	11
Audit	11
Termination of the study	12
Funding	12
Indemnity	12
Ethics approval and research governance	12
Chapter 3 Results	13
Recruitment	13
Participant flow	13
Summary of ineligible and non-recruited patients	14
Characteristics used for stratification of randomisation	15
Characteristics at pre-assessment	15
Patient characteristics at randomisation	15
Adherence to trial protocol	15
<i>Adherence to trial medication</i>	15
<i>Adherence to the trial visits and withdrawal</i>	22
<i>Adherence to study blinding</i>	24
<i>Adherence to trial procedures</i>	25
Concomitant medication	25
Outcomes and estimation	25
<i>Primary outcome</i>	25
<i>Secondary outcome: clinical recurrence</i>	25
<i>Secondary outcome: surgical intervention</i>	27
<i>Secondary outcome: endoscopic recurrence</i>	29
<i>Secondary outcome: faecal calprotectin levels</i>	31
<i>Secondary outcome: thioguanine nucleotide concentration levels</i>	34
<i>Secondary outcome: changes in self-rated quality-of-life scores</i>	34
Safety outcomes	35
<i>Adverse events</i>	35
<i>Deaths</i>	36
<i>Pregnancy</i>	37
<i>Safety blood monitoring</i>	37
<i>Prespecified subgroup analyses of primary and secondary outcomes</i>	41
Chapter 4 Discussion	47
Context	47
Limitations	47
Strengths	48
Applicability in UK hospitals and beyond	48
Reducing variance in clinical practice	49
Potential risks not explored in this study	49
Unanticipated findings	49
Patient public involvement	49
Chapter 5 Conclusions	51
Implications for health care	51
Recommendations for research	51
Acknowledgements	53
References	57

List of tables

TABLE 1 Dose of MP for patients with normal TPMT	8
TABLE 2 Dose reduction schedule	8
TABLE 3 Ineligible and non-recruited patients across participating centres	14
TABLE 4 Number of patients randomised at each recruiting centre	16
TABLE 5 Smoking status of randomised patients	16
TABLE 6 Patient characteristics at pre-assessment	17
TABLE 7 Patient characteristics at randomisation	19
TABLE 8 Duration of trial medication	21
TABLE 9 Reasons for randomised patients not completing 3 years of trial medication	22
TABLE 10 Summary of doses at first and final visit	23
TABLE 11 Summary of doses at final visit, compared with dose first allocated	23
TABLE 12 Summary of withdrawal at final study visit (week 157 post randomisation)	23
TABLE 13 Length of patient follow-up	24
TABLE 14 Emergency unblinding by treatment allocation with reasons	24
TABLE 15 Protocol deviations by category	25
TABLE 16 Summary of concomitant medication	26
TABLE 17 Summary of primary outcome	26
TABLE 18 Primary outcome statistical analysis (Cox proportional hazards model)	27
TABLE 19 Follow-up and recurrence	27
TABLE 20 Summary of secondary outcome events	27
TABLE 21 Secondary statistical analysis (Cox proportional hazards model)	27
TABLE 22 Surgical interventions: time to surgical intervention	28
TABLE 23 Surgical interventions: time (days) to surgical intervention	28
TABLE 24 Summary of colonoscopy results defined by Rutgeerts score and categorised by score	29
TABLE 25 Summary of colonoscopy results defined by Rutgeerts score as either negative or positive	30

TABLE 26 Visit 12 colonoscopy analysis results	30
TABLE 27 Visit 12 treatment effect for CDEIS score	31
TABLE 28 Faecal calprotectin levels by colonoscopy result at visit 6	33
TABLE 29 Faecal calprotectin levels by colonoscopy result at visit 12	33
TABLE 30 Analysis of faecal calprotectin as a time-varying covariate (Cox proportional hazards model)	34
TABLE 31 Analysis of TGN as a time-varying covariate (patients receiving MP only) (Cox proportional hazards model)	35
TABLE 32 Summary of reported adverse events	37
TABLE 33 Summary of reported serious adverse events	38
TABLE 34 Reported pregnancies	39
TABLE 35 Blood safety monitoring: % of out of range values by visit and treatment group	40

List of figures

FIGURE 1 The CONSORT diagram for TOPPIC	13
FIGURE 2 Kaplan–Meier plot showing duration of trial medication in years	22
FIGURE 3 Mean change from baseline in CDAI scores per study visit	28
FIGURE 4 Colonoscopy by study visit (visit 6 was week 49 post randomisation and visit 12 was week 157 post randomisation)	30
FIGURE 5 Crohn’s Disease Endoscopic Index of severity score by study visit (visit 6 was 49 weeks post randomisation and visit 12 was 157 weeks post randomisation)	31
FIGURE 6 Mean change from baseline in faecal calprotectin level	32
FIGURE 7 Categorical summary of faecal calprotectin levels ($\mu\text{g/g}$) in faeces	32
FIGURE 8 Mean change from baseline in TGN levels	34
FIGURE 9 Categorical summary of TGN levels ($\text{pmol}/8 \times 10^8$ red blood cells)	35
FIGURE 10 Change from baseline final model treatment effects and 95% CIs for overall average IBDQ	36
FIGURE 11 Change from baseline final model treatment effects and 95% CIs for overall total IBDQ	36
FIGURE 12 Forest plot of primary outcome (unadjusted)	42
FIGURE 13 Forest plot of secondary outcome (unadjusted)	43
FIGURE 14 Forest plot of colonoscopy results at visit 12 (unadjusted)	44
FIGURE 15 Forest plot of CDEIS score at visit 12 (unadjusted)	45

List of supplementary material

Report Supplementary Material 1 Trial electronic case report form

Report Supplementary Material 2 Statistical analysis plan

Report Supplementary Material 3 Summary of protocol amendments

Report Supplementary Material 4 Overview of participant information and consent forms

Supplementary material can be found on the NIHR Journals Library report project page (www.journalslibrary.nihr.ac.uk/programmes/eme/0980004/#/documentation).

Supplementary material has been provided by the authors to support the report and any files provided at submission will have been seen by peer reviewers, but not extensively reviewed. Any supplementary material provided at a later stage in the process may not have been peer reviewed.

List of abbreviations

CD	Crohn's disease	IBD	inflammatory bowel disease
CDAI	Crohn's Disease Activity Index	IBDQ	Inflammatory Bowel Disease Questionnaire
CDEIS	Crohn's Disease Endoscopic Index of Severity	MP	mercaptopurine
CI	confidence interval	MRC	Medical Research Council
CONSORT	Consolidated Standards of Reporting Trials	POCER	Post-Operative Crohn's Endoscopic Recurrence study
DMC	Data Monitoring Committee	TGN	thioguanine
ECCO	European Crohn's and Colitis Organisation	TMG	Trial Management Group
ECTU	Edinburgh Clinical Trials Unit	TNF- α	tumour necrosis factor alpha
EME	Efficacy and Mechanism Evaluation	TOPPIC	Trial Of Prevention of Post operative Crohn's disease
EQ-5D	EuroQol-5 Dimensions	TPMT	thiopurine S-methyltransferase
HR	hazard ratio	TSC	Trial Steering Committee

Plain English summary

Crohn's disease (CD) is a serious disease causing a swelling and ulceration of the gut wall. Most patients are treated with medicines but, after 10 years, two out of three people with CD need an operation. CD can often come back after an operation, and almost half of those who have one will need another one.

Several medicines have been tested to see if they help stop CD coming back after an operation. Azathioprine and mercaptopurine (MP) are medicines called thiopurines that alter the way that the immune system works. Over the last 10 years, they have become widely used for CD when it is not easily treated with other medicines but is not serious enough to need an operation. They have also been tested to see if they can stop CD coming back after an operation, but previous studies were relatively small and did not look at all relevant measures, so there was a need for a large modern study to look at the role of thiopurines again.

The Trial Of Prevention of Post operative Crohn's disease (TOPPIC) was a double-blind, randomised controlled trial done to find out whether the use of MP after an operation can prevent or delay CD coming back. Following informed consent, 240 patients were recruited into the study between 2007 and 2012 and randomly got either a daily dose of MP or matching placebo for 36 months. Data and samples were collected regularly during the study.

Mercaptopurine reduced how often CD came back after an operation only in smokers, who were also the people most at risk of recurrence.

Scientific summary

Background

Crohn's disease (CD) is a debilitating condition of unknown cause in which there is inflammation of the wall of the gut. This may result in diarrhoea, abdominal pain, weight loss, tiredness and feeling generally unwell. The disease commonly affects young people, affecting education, employment and family life. Most patients are first treated medically, but over the first 10 years of the condition up to 65% of patients will need an operation to control the disease. Recurrence of CD following surgery is almost universal, most commonly occurring at the anastomosis (join) between the two sections of bowel. In excess of 40% of these individuals will need further surgery to again control the disease within 10 years. A number of medications have been tested previously to prevent or delay the recurrence of CD. The 5-aminosalicylates drugs are ineffective and nitroimidazole antibiotics have some effect but cannot be taken in the long term because of their side effects. Azathioprine and mercaptopurine (MP) (collectively termed thiopurines) are drugs that alter the way that the immune system responds. They are well established in the maintenance of steroid-induced remission in CD. They have been tested to prevent the postoperative recurrence, but the studies have been flawed and results mixed.

Objectives

The primary objective of this study was to determine definitively if MP could prevent or delay postoperative clinical recurrence of CD when compared with placebo. Secondary objectives included determining if MP could prevent or delay endoscopic recurrence of CD using the Rutgeerts scoring system, whether or not endoscopic recurrence could predict clinical recurrence, the relationship between faecal calprotectin or 6-thioguanine nucleotide levels and clinical efficacy, and changes in self-rated quality-of-life scores.

Methods

This was a multicentre, parallel-group, double-blind, randomised controlled trial conducted in the UK (29 sites). Patients were eligible for the trial if they were aged ≥ 16 years in Scotland and ≥ 18 years in England and Wales, had an ileocolic or small bowel resection ≤ 3 months before randomisation during which all observable disease was removed, and had a histologically confirmed diagnosis of CD (according to the Lennard-Jones criteria). Patients were excluded if they had a known intolerance or hypersensitivity to thiopurines, were known to require further surgery, underwent strictureplasty alone, had a stoma, had an active or untreated malignancy, or had absent thiopurine S-methyltransferase (TPMT) activity. Prior to randomisation, any postoperative infections were fully treated and existing treatments for CD were stopped.

Intervention

The intervention was randomisation to either a daily oral dose of MP or placebo, with dose adjustment according to body weight (kg) and TPMT status. Following informed signed consent, patients were allocated 1 : 1 to the trial intervention. All clinicians and the study staff involved in day-to-day trial management and outcome assessment were blinded to the study allocation. Blood samples for genetic and serological analysis were taken at randomisation with additional blood and stool samples collected at weeks 0, 13, 49, 103 and 157 for central analysis of drug metabolite and faecal calprotectin levels, with endoscopic assessment at weeks 49 and 157. All clinicians caring for patients and study staff involved in day-to-day trial management and outcome assessment were blinded to study allocation.

Main outcome measures

The primary end point was clinical recurrence of CD [Crohn's Disease Activity Index (CDAI) score of > 150 points plus 100-point rise] and the need for anti-inflammatory rescue therapy or primary surgical intervention. We also looked at the secondary outcome of clinical recurrence defined by a CDAI score of ≥ 150 points together with a 100-point rise in the CDAI score from baseline or anti-inflammatory rescue therapy, or primary surgical intervention. In addition, we looked at endoscopic recurrence using the Rutgeerts scoring system and Crohn's Disease Endoscopic Index of Severity (CDEIS) score, faecal calprotectin levels, thioguanine (TGN) levels and changes in self-rated quality-of-life scores using the Inflammatory Bowel Disease Questionnaire (IBDQ) and EuroQol-5 Dimensions (EQ-5D).

All analyses were intention to treat. The primary outcome variable was postoperative recurrence of CD and its timing if it recurred. Analysis was intention to treat and based on the application of the Cox proportional hazards model. The primary analysis included terms for treatment, the variables on which the randomisation was stratified (smoking status and recruitment site) and adjusted for baseline values of previous treatment with MP and previous treatment with azathioprine. The adjusted analysis was considered to be the primary analysis of the primary outcome. Adjusted Cox proportional hazard ratios (HRs) were presented as the comparison of MP versus placebo, with a HR of < 1 indicating a treatment effect in favour of MP.

The secondary outcome variable of clinical recurrence was analysed in the same manner as the primary outcome. For both primary and secondary outcomes, the adjusted analysis was considered the primary analysis. Endoscopic recurrence using both the Rutgeerts and CDEIS scoring systems were summarised by time and treatment group. Colonoscopy results at week 157 post randomisation (study visit 12) were compared between the treatment groups using a chi-squared test. CDEIS scores at week 157 post randomisation were compared between treatment groups using a *t*-test. Results of faecal calprotectin levels were summarised by time and treatment group, both as a continuous measure and categorically. Faecal calprotectin and TGN levels of the MP drug metabolite were incorporated separately into a Cox proportional hazards model as time-varying covariates. Quality of life, as measured by the IBDQ, was analysed using a change from baseline repeated measures analysis of covariance to evaluate the effect of treatment over time for the overall average IBDQ score and also the overall total IBDQ score. Quality of life, as measured by the EQ-5D, was summarised by treatment group across study visits. We also carried out prespecified subgroup analyses of the primary and secondary outcomes to assess for a treatment effect in terms of thiopurine naivety, previous treatment with infliximab or methotrexate, previous surgery, smoking status, duration of disease and age at diagnosis. The interaction between subgroup and treatment was included in the Cox regression model to determine if the treatment effect differed by subgroup. The same subgroups analysed for the primary and secondary outcomes were also analysed with respect to colonoscopy results and CDEIS scores.

Results

Between June 2008 and April 2012, 240 patients were enrolled and received at least one dose of study drug. A total of 128 (53%) participants were randomised to receive MP and 112 (47%) were randomised to receive placebo. A protocol violation was recorded involving a participant who was prescribed a study drug from the wrong treatment arm 6 weeks post randomisation; the error was reported and correct study drug issued. The study was completed as planned with an extension to the originally proposed recruitment period. No randomised patients were excluded from the analysis. More patients achieved the primary end point in the placebo ($n = 26$, 23.2%) group than in the MP group ($n = 16$, 12.5%), with an adjusted *p*-value of 0.073 [HR 0.535, 95% confidence interval (CI) 0.27 to 1.06]. Smokers were more likely to reach the primary end point than non-smokers (HR 0.127, 95% CI 0.04 to 0.46 among smokers; HR 0.898, 95% CI 0.42 to 1.94 among non-smokers; $p = 0.018$). The proportion of patients experiencing adverse events was similar in the treatment and placebo groups. Likewise, there was little difference in the per-patient number of adverse events between the groups.

At baseline prior to randomisation, 146 participants (60.8%) of the whole cohort were female and 55 (22.9%) participants of the whole cohort were smokers. There were no differences between participants at randomisation in terms of weight, faecal calprotectin levels, or CDAI or IBDQ scores.

A total of 128 (53%) participants received MP and 112 (47%) received the placebo. A total of 104 (43.3%) participants received trial medication for the full 3-year treatment period. Overall, the mean period of treatment was 22.6 months (maximum treatment time possible: 36 months). In the MP group, the mean treatment period was 23.4 months, compared with 21.8 months in the placebo group. Adherence to trial protocol resulted in a dose reduction over the course of the study in 39.1% of participants on MP versus 16.1% on placebo. Consequently, 61 out of 102 patients on MP who had TGN levels measured at week 49 post randomisation were on subtherapeutic drug doses ($< 235 \text{ pmol}/8 \times 10^8$ red blood cell count). Trial medication was stopped in 37.5% of participants on MP versus 42.9% of participants on placebo. The reasons for discontinuation of trial medication were adverse events (58.8%), regular safety blood monitoring results (13.2%), early withdrawal (15.4%), loss to follow-up (11.8%) and death (0.7%). Follow-up data were not available for all participants for the following reasons: early withdrawal [21 participants (8.7%)], loss to follow-up [16 participants (6.6%)] and death [one participant (0.4%)].

Clinical recurrence of CD occurred in 42 (17%) participants: 16 out of 128 (12.5%) on MP versus 26 out of 112 (23.2%) on placebo (HR 0.535, 95% CI 0.27 to 1.06; $p = 0.073$). Of the 42 who reached the primary end point, 37 participants (88%) met the CDAI score trigger and had rescue therapy initiated, whereas five (12%) met the CDAI score trigger and had both rescue therapy and primary surgical intervention.

In the entire study cohort, the incidence of clinical recurrence was higher in smokers than among non-smokers [15/55 (27.3%) vs. 27/185 (14.6%); $p = 0.018$]. Among the smokers, 3 out of 29 on MP (10.3%) experience clinical recurrence, compared with 12 out of 26 (46.2%) on placebo, demonstrating that MP was effective at preventing postoperative recurrence in smokers (HR 0.127, 95% CI 0.04 to 0.46) but not in non-smokers (HR 0.898, 95% CI 0.42 to 1.94). Other subgroup analyses assessing previous thiopurine exposure, prior methotrexate use, prior infliximab use, previous surgery and age at diagnosis did not identify any differences between the groups.

The overall number of clinical recurrence secondary outcomes (defined by a CDAI score rise, or rescue therapy or surgery) was 34 (26.6%) in the treatment arm and 40 (35.7%) in the placebo arm, with an adjusted p -value of 0.243 (HR 0.737, 95% CI 0.44 to 1.23). Subgroup analyses for the secondary outcomes demonstrated no statistically significant differences between subgroups, with the exception of smokers.

The overall number of patients with endoscopic recurrence [defined as a Rutgeerts score of $\geq i2$ (≥ 5 aphthous lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis) at week 157 post randomisation] was 29 (32.6%) in the treatment arm and 28 (38.9%) in the placebo arm, with an adjusted p -value of 0.382 (odds ratio 0.66, 95% CI 0.26 to 1.67).

There were no significant differences in endoscopic recurrence, as defined by the Rutgeerts score, by treatment group on subgroup analyses except in the thiopurine-naive group. CDEIS scores at visits 6 and 12 were higher in the placebo group than in those allocated to MP, although this difference was not statistically significant.

Analysis of faecal calprotectin levels as a time-varying covariate indicated that, for every 100- $\mu\text{g}/\text{g}$ increase in faecal calprotectin, the hazard of reaching the primary end point increased by 17.7% (HR 1.177, 95% CI 1.082 to 1.282; $p = 0.0002$).

There was no statistically significant association between TGN concentrations and the primary end point (HR 0.800, 95% CI 0.565 to 1.132; $p = 0.207$).

The statistical analysis of patient-reported outcome measures (as measured by IBDQ) showed no significant difference between treatment and placebo groups across all study visits, the overall average across the study as a whole, and for the total IBDQ score.

Of 1747 reported adverse events, 355 (20.3%) were infections, of which only seven (0.4%) necessitated hospitalisation. Higher rates of adverse event reporting were seen in the group of patients allocated to placebo. The majority of adverse events were classed as either mild or moderate in severity [868 (91.6%) in the MP group and 728 (91.1%) in the placebo group]. Adverse events caused discontinuation of treatment in 80 patients overall (33%): 39 of the 128 (30%) patients in the MP group versus 41 of the 112 (36.6%) patients in the placebo group. There were two cases of pancreatitis among the overall 1747 reported adverse events (0.1%: one in the MP group and one in the placebo group) and four malignancies (0.2%: three in the MP group and one in the placebo group): basal cell carcinoma, breast cancer and two cases of lentigo maligna. One participant in the placebo group died of coronary heart disease.

There were 14 pregnancies reported during the course of the trial, with 12 normal children and maternal outcomes. We observed one spontaneous abortion at approximately 21 weeks' gestation and one congenital anomaly (heart murmur, septal defect and hydrocephalus) in the infant of a patient in the placebo group.

Conclusions

The Trial Of Prevention of Post operative Crohn's disease (TOPPIC) is the largest double-blind trial assessing the use of thiopurines to prevent postoperative recurrence in CD. From the trial itself, MP was not effective in reducing the frequency of clinical postoperative recurrence of CD overall, but the data suggest that it has clinically meaningful effect among the subgroup of patients who continue to smoke after surgery.

Recommendations for research

The trial results raise the following questions:

1. What is the impact of smoking cessation in this population and what are the mechanisms of action of smoking on increasing disease recurrence?
2. Could faecal calprotectin levels be used as a surrogate for endoscopic assessment?
3. What would the impact on the overall results have been if dosage levels had been informed throughout the duration of the trial by the use of metabolite data, and could these data be used to deliver treatment more effectively?
4. What are the factors behind an apparent discrepancy between clinical and endoscopic recurrence?
5. What are the long-term effects of MP in this population?

Future work

Exploratory analyses of possible predictors of disease recurrence using collected data and samples should be undertaken. Biomarker discovery to stratify high-risk responders should also be researched in more detail.

Trial registration

This trial is registered as ISRCTN89489788 and EudraCT 2006-005800-15.

Funding

This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership.

Chapter 1 Introduction

Crohn's disease (CD) is a chronic, relapsing, inflammatory illness that can involve any part of the gastrointestinal tract, but most commonly involves the terminal ileum. The prevalence in northern England has been estimated to be 144 per population of 100,000.¹ The incidence among young people in Scotland is the highest in the UK, and continues to rise.² Although the mortality associated with CD is low, there is significant morbidity, with serious effects on growth, development, education and employment potential.

Crohn's disease treatment

Treatment algorithms for the medical management of active CD have evolved very rapidly in recent years, and the relative importance of thiopurines in induction of remission, and in maintenance, has been re-evaluated since this study was first designed. Although steroids, biological therapies and combination therapies (biologics used together with thiopurine agents) have an evidence basis for induction of remission, a recent Cochrane review suggested that there was no place for monotherapy with thiopurine in induction of remission.³

However, for patients entering medically induced remission, immunosuppression with azathioprine or mercaptopurine (MP) is an effective maintenance strategy (odds ratio 3.17, number needed to treat 3.3 favouring 2 mg/kg azathioprine over placebo), offering an acceptable balance of efficacy, tolerability and cost.⁴ The relative merits of monotherapy with thiopurines alone, anti-tumour necrosis factor alpha (TNF- α) agents or combination regimes of thiopurines and biological agents remain contentious in this setting of maintenance therapy.

Despite current medical therapy, up to 50% of patients have aggressive disease and require surgery within 5 years of diagnosis.⁵ Unfortunately, disease relapse rates are high within 2 years of surgery for both endoscopic (72–98%) and clinical recurrence (37–70%).⁶ Re-operation rates cumulate at 5% of patients per year.⁷

Evidence for postoperative use of thiopurines

The development of strategies to prevent or delay postoperative recurrence of CD is therefore of major clinical importance; however, there is a paucity of evidence to support any particular drug strategy.^{8,9} The thiopurines, azathioprine and MP have an established role in inducing remission in CD and in the maintenance of medically induced remission. These agents have historically been suggested in treatment algorithms for patients at 'high risk' of postoperative relapse, but the evidence basis for their use in this context, and indeed the evidence that clinical parameters may predict patients at 'high risk' of relapse, is weak.⁷ A meta-analysis conducted by Jones *et al.*¹⁰ found that the efficacy data for thiopurines in the postoperative setting were inconclusive and, aside from smoking, there were no consistent predictors of postoperative relapse. A 2014 Cochrane review also concluded that, although there was evidence to suggest that thiopurines may reduce endoscopic and clinical recurrence, the quality of evidence was degraded by small numbers and flawed study designs.³ The value of thiopurine metabolites in this situation is unknown.¹¹ More recently, the role of biological therapies in postoperative prophylaxis has received considerable attention. Following smaller randomised studies of infliximab in postoperative disease, the recent Post-Operative Crohn's Endoscopic Recurrence (POCER) study demonstrated that targeted escalation of immune-modulatory therapy (thiopurines followed by adalimumab) in patients with early endoscopic evidence of recurrence may delay subsequent endoscopic, although not clinical, recurrence.^{11–13}

Current practice

Currently no medical therapy is licensed to prevent postoperative recurrence in CD. As well as thiopurine agents and anti-TNF- α agents, 5-aminosalicylates, corticosteroids and metronidazole have all been suggested, but the evidence in favour of these drugs is weak and none is widely used in the UK.⁶ Postoperative maintenance therapy with azathioprine or MP is more widely used and is included in a number of clinical algorithms, but trial data from controlled trials available thus far have failed to demonstrate whether or not this is an effective therapy. Existing studies have been underpowered, poorly designed or used an inappropriate drug dose.^{6,14-19}

For these reasons, we consider that evidence-based strategies to prevent postoperative recurrence are both an unmet clinical need and a research priority.

Controversies in use of thiopurines in postoperative use

As we discussed in our recent review (see Jones *et al.*¹⁰), there are many unresolved controversies associated with the use of thiopurines in the prevention of postoperative recurrence in CD, and this remains contentious. The definition of recurrence itself, specifically the distinction between endoscopic, clinical and surgical recurrence, the identification of high-risk individuals, the influence of pre-operative therapies on responsiveness, and the relative merits of thiopurines compared with anti-TNF- α therapies are key issues; however, no real evidence-based consensus has emerged.¹⁰ The European Crohn's and Colitis Organisation (ECCO) 2010 guidelines recommend their use postoperatively in 'high-risk' patients (defined as smokers and those with previous intestinal surgery, penetrating disease, perianal disease or extensive small bowel section).²⁰ The British Society of Gastroenterology's guidelines are more cautious in emphasising the weak evidence base for risk factors in predicting disease recurrence (with the exception of smoking) and for the use of thiopurines in this setting.⁸

The use of thiopurines by women, or the male partners of women, trying to conceive or in pregnancy

With respect to safety, use in patients of childbearing age has been a key issue. When the trial commenced, the published guidelines of both ECCO and the British Society of Gastroenterology supported the use of thiopurines in inflammatory bowel disease (IBD) in women of childbearing potential and during pregnancy on the grounds that the risk to the unborn child from disease activity appeared greater than continued therapy. As part of the initial trial assessment by the Medicines and Healthcare products Regulatory Agency, supporting documentation was reviewed and the inclusion of women of childbearing potential was approved without inclusion criteria of agreement to the use of contraceptives. No comment was made for inclusion of males who could potentially father a child while receiving MP. However, the sponsor, Trial Management Group (TMG) and Trial Steering Committee (TSC) examined this position in more detail in 2010.

The TMG and TSC considered the evidence and decided not to exclude female patients who either were planning to become pregnant or became pregnant, or male patients whose partners were planning to become pregnant. The existing patient information sheets, however, were revised to detail the potential risks to male patients. All enrolled male patients were also reconsented to the new information sheets and consent forms. Pregnancy data were also included in the TSC and Data Monitoring Committee (DMC) standard reports.

Since 2010, several large studies have been published examining thiopurine use for IBD during pregnancy, which provided further support for the initial guidelines. The Cancers Et Surrisque Associé aux Maladies inflammatoires intestinales En France (CESAME) study group examined 215 pregnancies in 204 women and concluded that thiopurine use during pregnancy was not associated with increased risks, including an

increased risk of congenital abnormalities.²¹ This has been supported by the findings of two further studies published in 2013 and 2014: Casanova *et al.*²² included a cohort of 187 pregnancies in participants using thiopurines in IBD and found no evidence of an increased risk of complications, whereas Ban *et al.*²³ included a cohort of 115 pregnancies in participants using thiopurines for CD and found no evidence of an increased risk of major birth defects.

Potential health-care impact

The present study has an important potential impact on health care in terms of defining, with accuracy, the clinical effectiveness of thiopurine therapy in the prevention of postoperative relapse. The data from the study overall suggest that routine postoperative use of MP in all patients undergoing surgery is not justified as a preventative measure. The subgroup analyses have helped identify smokers as the subgroup of individuals at highest risk of relapse, and helped to demonstrate that this subgroup is most likely to benefit from thiopurine therapy, thereby helping to target immunomodulatory therapy towards patients most likely to benefit. The important secondary objectives allowed comparison of clinical and endoscopic recurrence rates, and analysis of clinical as well as biomarker predictors of disease recurrence. Importantly, we have assessed age, the need for previous surgery, previous thiopurine use and smoking as potential determinants of outcome.

Rationale for research

At present, there is no widely accepted algorithm or management plan in preventing postoperative relapse of CD. Non-evidence-based algorithms have been widely used and the present study will allow clear evidence to be defined in the largest study carried out in the use of thiopurine therapy.

The secondary objectives allowed comparison of clinical and endoscopic recurrence rates, and the effects of thiopurine therapy on each of these aspects. The study design has also allowed examination of drug safety, tolerability and adherence to therapy. The biomarkers in the study allow the relative predictive value of faecal calprotectin levels in assessing recurrence to be defined, as well as the relationship between thiopurine use and calprotectin levels. Quality of life was also measured in the present study. The primary objective of this study was to assess if MP can prevent or delay postoperative recurrence in CD.

Study aims

The primary objective of the Trial Of Prevention of Post operative Crohn's disease (TOPPIC) was to assess if MP can prevent or delay postoperative recurrence of CD.

Secondary objectives included if MP can prevent or delay endoscopic evidence of recurrence and, finally, whether or not endoscopic recurrence can predict clinical recurrence, whether or not faecal calprotectin levels can be used as a non-invasive marker of disease recurrence that may remove the need for colonoscopy in some patients, whether or not drug metabolite levels relate to clinical efficacy of MP, and whether or not we can predict postoperative recurrence using clinical, genetic or serological data.

Development of TOPPIC

Development of TOPPIC was initiated in 2006 by a team of collaborators based in Scotland, with ethics and clinical trial authorisation sought in 2007. The trial was extended throughout the UK in 2010 to include collaborators from across England and Wales.

Chapter 2 Methods

Trial design

This was a multicentre, parallel-group, double-blind, randomised controlled study conducted in the UK (29 sites). Participants were allocated 1 : 1 to active treatment with MP or a matching placebo.

Following slower than projected recruitment in the first 24 months, the protocol was modified to reduce the number of colonoscopies performed as part of the trial and to allow the inclusion of patients with a previous history of malignancy, providing that they had been in remission for 5 years.

Participants

Participants were adults aged ≥ 16 years in Scotland (≥ 18 years in England and Wales) with a histologically confirmed diagnosis of CD (according to the Lennard-Jones criteria) undergoing ileocolonic or small bowel resection.²⁴ Patients were approached ≤ 3 months after surgery during the perioperative period and, following consent for screening, underwent a screening assessment consisting of a blood sample to check thiopurine *S*-methyltransferase (TPMT) activity and a postoperative stool sample to exclude enteric infection.

One week prior to randomisation, eligible participants underwent standard safety blood tests (including checks of liver function, haemoglobin levels, and white blood cell, neutrophil and platelet counts) in addition to a urinary pregnancy test.

Inclusion and exclusion criteria are described in the following sections.

Inclusion criteria

- Aged ≥ 16 years in Scotland and ≥ 18 years in England and Wales.
- Established diagnosis of CD confirmed at recent resection.
- Ileocolonic or small bowel resection ≤ 3 months before screening.
- Had ≤ 100 cm of fixed small bowel resected in total; a previous ileocolonic resection was accepted.
- Able to start oral nutrition in the first 2 postoperative weeks.
- Normal or heterozygous TPMT (activity present or reduced, consistent with carrier status).
- Able to provide written informed consent prior to screening and comply with the requirements of the study protocol.
- Not taking antibiotics at least 2 weeks prior to randomisation.

Exclusion criteria

- Pregnancy at baseline or breastfeeding.
- Known hypersensitivity or intolerance to MP.
- Pancreatitis associated with azathioprine.
- Receiving experimental treatment for CD ≤ 4 weeks prior to study entry.
- Known to require further surgery at study entry (i.e. for the removal of an abscess developing from the primary surgery).
- Strictureplasty procedure alone (strictureplasty and resection procedure together will not be considered an exclusion criterion).
- Presence of a stoma.

Identifying participants

The study aimed to recruit and randomise from participating sites. Potentially eligible patients were identified by clinicians and research/specialist nurses at sites following ileocolonic or small bowel resection.

Settings and locations where the data were collected

The study took place in the following tertiary referral hospitals in the UK: Western General Hospital, Edinburgh; Aberdeen Royal Infirmary, Aberdeen; Ninewells Hospital, Dundee; Glasgow Royal Infirmary and Stobhill Hospital, Glasgow; Royal Devon and Exeter Hospital, Exeter; University Hospital Coventry, Coventry; Royal Liverpool University Hospital, Liverpool; Manchester Royal Infirmary, Manchester; Bristol Royal Infirmary, Bristol; University College Hospital, Royal Free Hospital and Royal London Hospital, London; John Radcliffe Hospital, Oxford; Salford Royal Hospital, Salford; Singleton Hospital, Swansea; Torbay Hospital, Torquay; Southampton General Hospital, Southampton; County Durham and Darlington Memorial Hospitals, Durham and Darlington; Royal Stoke University Hospital, Stoke-on-Trent; Queen's Medical Centre, Nottingham; St Mark's Hospital, Harrow; Rotherham General Hospital, Rotherham; Queen Elizabeth Hospital, Birmingham; and Raigmore Hospital, Inverness. Randomisation was open from May 2008 until June 2012 (a total of 49 months).

Interventions

The intervention was a random allocation to MP in 50-mg tablets or placebo in identical 50-mg tablets and matched packaging supplied to sites by the manufacturer.

Outcomes

The primary study outcome was clinical recurrence of CD defined by a Crohn's Disease Activity Index (CDAI) score of ≥ 150 points together with a 100-point rise in the CDAI score from baseline, with the need for anti-inflammatory rescue therapy or primary surgical intervention.²⁵

The secondary study outcomes were as follows:

- clinical recurrence defined by a CDAI score of ≥ 150 points together with a 100-point rise in the CDAI score from baseline, or anti-inflammatory rescue therapy or primary surgical intervention
- the need for a second operation to remove recurrent CD from the anastomotic site
- endoscopic recurrence using the Rutgeerts and Crohn's Disease Endoscopic Index of Severity (CDEIS) scoring systems^{26,27}
- faecal calprotectin levels
- thioguanine (TGN) levels
- changes in self-rated quality-of-life scores.

Measurements

Following patient consent for screening, the trial screening process consisted of analysis of TPMT activity and a postoperative stool sample to exclude enteric infection. One week prior to randomisation, eligible participants underwent blood tests (including liver function tests, haemoglobin concentration tests, and white blood cell, neutrophil and platelet counts) and a urinary pregnancy test. Patients returned to designated clinics run by clinical teams for a baseline assessment including the CDAI, patient-reported outcome measures including the Inflammatory Bowel Disease Questionnaire (IBDQ), a physical examination

and a blood sample for assay of drug metabolite level.²⁸ Additional blood samples for genetic and serological analysis were also taken, and results are reported separately.

Patients were randomised at baseline to receive either MP or placebo. MP was given at a dose of 1–1.5 mg/kg of body weight, rounded to the nearest 25 mg as a single daily dose in the morning. Patients with low TPMT activity were prescribed MP at half the normal dose. Treatment was on a maintenance basis for 3 years, with the dose adjusted up or down for weight changes during the study.

Follow-up data were collected at 10 time points, at weeks 6, 13, 31, 49, 67, 85, 103, 121, 139 and 157 post randomisation. At each visit, the following data were collected: CDAI score, physical characteristics (as measured by examination), concomitant medications taken and patient-reported outcomes including the IBDQ. At weeks 0, 13, 49, 103 and 157 post randomisation, patients were also asked to provide additional stool and blood samples for the central assessment of faecal calprotectin and TGN metabolite levels, with endoscopic assessment at weeks 49 and 157 post randomisation.

Sample processing

Stool samples were collected at participating centres and frozen on site at –80 °C. Samples were then shipped on dry ice in two batches during 2014 and 2015 to a central biochemistry laboratory at NHS Lothian Western General Hospital in Edinburgh. Faecal calprotectin levels were all assessed using the CALPRO® calprotectin enzyme-linked immunosorbent assay (alkaline phosphatase) (NovaTec Immundiagnostica GmbH, Dietzenbach, Germany) and processed by technicians blinded to the treatment allocation. Blood samples for TGN testing were sent ambient to Viapath (formerly GSTS Pathology; London, UK) for analysis in the Purine Research Laboratory. An independent analyst blinded to the treatment allocation then assessed each level.

Therapeutic monitoring

All patients underwent regular safety blood monitoring every week for the initial 6 weeks and thereafter at 6-weekly intervals as long as the patient remained on the study drug. Blood samples were processed at participating site laboratories. An independent central clinician who was blinded to the treatment allocation reviewed results. Prespecified dose reduction or cessation then occurred in the event of abnormal monitoring parameters. In the event of patient intolerance (profound nausea or persistent influenza-like symptoms), protocol-driven dose reduction was also undertaken. If abnormal parameters improved after a temporary stop, treatment was started again at a lower level. The central clinicians, blinded to the treatment allocation, made all of these decisions.

To protect blinding, a programme of sham dose reductions was planned for patients on placebo. On the advice of the DMC these were not undertaken, although the investigators were not informed of this decision, hence protecting the study blinding.

Dose changes

All randomised patients allocated to the treatment group were given 1–1.5 mg/kg body weight, rounded to the nearest 25 mg, to be taken as single daily dose in the morning. Treatment was on a maintenance basis for 3 years or until the study drug was discontinued. Patients heterozygous for *TPMT* mutations were prescribed MP at half the normal dose. The dose was adjusted up or down for weight changes according to *Table 1*.

The blinded treatment of either MP or placebo could also be reduced or temporarily stopped following patient intolerance (profound nausea or persistent influenza-like symptoms) or abnormal blood safety

TABLE 1 Dose of MP for patients with normal TPMT

Body weight (kg)	Initial dose MP (mg)	Amount per body weight (mg/kg)
< 33	50 alternate days	1–1.5
33–49.9	50 daily	1–1.5
50–74.9	50/100 alternate days	1–1.5
75–99.9	100 daily	1–1.33
100–150	150 daily	1–1.5
> 150	200 daily	> 1

results. In these cases, the dose was reduced in accordance with *Table 2* and not increased again during the course of the trial. If symptoms or blood safety test result abnormalities persisted and were, in the view of the investigator, of sufficient severity, the drug could be stopped. One of the blinded clinicians assessing safety blood test results could also stop the drug.

Sample size

It was estimated that a study population of 182 evaluable patients would provide the trial with 80% power to detect a reduction in the frequency of recurrence from 50% in the placebo group to 30% in the treatment arm by 3 years at the 5% level of significance. Preliminary data from surgical and pathology databases at the five Scottish recruiting sites indicated that this was an achievable target. In 2006–7, approximately 130 ileocolonic resections were performed annually at the five Scottish recruiting sites initially proposed. We estimated that 60% of the potential patients could be recruited, giving a sample population of 234 patients and allowing for a 15% dropout rate. This would leave an evaluable population of 200 patients over 3 years.

These figures were based on an intention-to-treat analysis, with the number needed to treat in order to prevent one recurrence predicted to be five. It is notable that the treatment effect of 20% was lower than in previously conducted studies (40% reduction in mild CD lesions and 75% reduction in more severe lesions in Hanauer *et al.*,¹⁸ 25% in Ardizzone *et al.*¹⁹). We also judged a treatment effect of 20% to be appropriate because, given the side-effect profile of MP, it was arguable that a treatment effect of significantly < 20% would be of limited clinical significance.

The sample size chosen had 80% power to detect a reduction in the frequency of recurrence from 50% in the placebo group to 30% in the treatment arm by 3 years at the 5% level of significance.

TABLE 2 Dose reduction schedule

Initial dose of MP (mg)	Reduced dose of MP (mg)	Per cent reduction
50 alternate days	Stop	100
50 daily	50 alternate days	50
50/100 alternate days	50 daily	33
100 daily	50 daily	50
150 daily	50/100 alternate days	50
200 daily	100 daily	50

Interim analyses and stopping guidelines

An independent DMC reviewed trial data throughout the course of the trial, and there were no formal stopping rules. The study recruitment period was extended and additional sites in England and Wales were opened up to address concerns regarding the recruitment rate. Aside from this, the trial recruited according to plan.

Randomisation

Sequence generation

Randomisation was by a central, internet-based, secure password-protected randomisation database. Patient identifiers and some clinical details were entered to confirm eligibility (inclusion and exclusion criteria) and to prevent re-recruitment. The random allocation sequence was generated by the programmers at a UK Clinical Research Collaboration-registered trials unit [Edinburgh Clinical Trials Unit (ECTU)].

Type of randomisation

Randomisation was stratified according to smoking status at baseline (yes/no) and by recruiting site (31 blocks in total).

Implementation

Patients were individually enrolled by clinicians and research/specialist nurses at participating centres (predominantly nursing staff) to one of the two parallel treatment groups. Randomisation had to be within ≤ 3 months of surgery.

Once the randomisation procedure had been completed, a prescription was generated and provided to the participant by a research nurse. The prescription contained details of the number of tablets and bottle codes. The participant was asked to take the prescription to the site pharmacy to receive their allocated blinded treatment. All subsequent prescriptions were generated and processed in the same way.

Blinding

Trial medication and packaging were identical in appearance. All study staff involved in the day-to-day management of the trial, hospital staff and patients were blind to the study intervention. It was not possible to tell which treatment a patient had been allocated from the study numbers, medication packets or prescriptions. To further reduce the opportunity for accidental unblinding, the routine safety blood test results were sent to a blinded central reader for assessment by an independent monitor at each participating site who was not involved in the day-to-day management of the trial or the patient. The clinicians assessing blood results and the study management team based in Edinburgh were blind to the assigned intervention. Blinding was broken only for patients in whom an urgent clinical need was identified in terms of their clinical management, typically following a CD relapse.

Trial data management

Trial data were manually entered into a web-based data collection system by researchers at participating sites. In this system, active server pages supported web-based electronic case report forms and queried a Microsoft SQL Server 2000 database (Microsoft Corporation, Redmond, WA, USA). Data were automatically encrypted (using Secure Sockets Layer protocol V3²⁹) when entered into the forms, transferred via the internet, decrypted and stored in a secure maintained network at the University of Edinburgh. The level of encryption was dependent on the client's web browser and operating system, but University of Edinburgh servers could offer up to 256-bit encryption. In the same network, data were then queried using statistical software (SAS; version 9.4, SAS Institute Inc., Cary, NC, USA) for the purposes of data analysis. All changes to electronic data by site staff were traceable by date and user. A copy of the trial electronic case report form is given in *Report Supplementary Material 1*.

Statistical methods

An analysis was undertaken using SAS. The full statistical analysis plan is given in *Report Supplementary Material 2*.

Primary outcomes

The primary outcome variable was postoperative recurrence of CD and its timing if it recurred. Analysis was intention to treat and was based on the application of a Cox proportional hazards model. The primary analysis included terms for treatment, the variables on which the randomisation was stratified (smoking status and recruitment site) and adjusted for baseline values of previous treatment with MP and previous treatment with azathioprine. Adjusted and unadjusted Cox proportional hazard ratios (HRs) are presented as the comparison of MP versus placebo (reference), with a HR of < 1 indicating a treatment effect in favour of MP. The adjusted analysis was considered to be the primary analysis of the primary outcome.

Secondary outcomes

The secondary outcome variable of clinical recurrence of CD (defined by a CDAI score of ≥ 150 points together with a 100-point rise in the CDAI score from baseline) or the need for anti-inflammatory rescue therapy or primary surgical intervention was analysed in the same manner as the primary outcome. For this secondary outcome, as for the primary outcome, the adjusted analysis was considered the primary analysis.

Endoscopic recurrence using both the Rutgeerts and CDEIS scoring systems was summarised by time and treatment group. Colonoscopy results at week 157 post randomisation (study visit 12) were compared between the treatment groups using a chi-squared test to compare the incidence of positive colonoscopies in the MP group and the placebo group. Both adjusted and unadjusted analyses were performed, with the adjusted analysis incorporating the same covariates as for the primary outcome, with odds ratios and 95% confidence intervals (CIs) presented. CDEIS scores at week 157 post randomisation were compared between treatment groups using a *t*-test. Adjusted and unadjusted analyses were performed, with treatment effects and 95% CIs presented. Faecal calprotectin results were summarised by time and treatment group, both as a continuous measure and categorically.

The use of faecal calprotectin levels as a non-invasive marker of disease recurrence was examined in two ways: first, it was considered as a time-dependent covariate in Cox proportional hazards model and, second, levels were compared descriptively between those with negative and positive colonoscopies (defined as negative if the Rutgeerts score was $< i2$ and positive if the Rutgeerts score was $\geq i2$) at weeks 49 and 157 post randomisation. Similarly, TGN levels of the MP drug metabolite were also considered as a time-dependent covariate in the Cox proportional hazards model.

The quality-of-life variables were analysed using repeated measures analysis of covariance to evaluate treatment and treatment by time interactions. Quality of life, as measured by the IBDQ, was summarised at each visit based on observed scores and change from baseline scores for each of the four IBDQ subscales (bowel symptoms, emotional health, systemic systems and social function). Averages and totals across all subscales were summarised similarly. In addition, the overall average and overall total scores were analysed using a change from baseline repeated measures analysis of covariance to evaluate the effect of treatment over time. Quality of life, as measured by the EuroQol-5 Dimensions (EQ-5D), was summarised by treatment group across study visits.

Subgroup analyses

Subgroup analyses of the primary and secondary outcomes were carried out to assess for a treatment effect in terms of thiopurine naivety, previous treatment with infliximab or methotrexate, previous surgery, smoking status, duration of disease and age at diagnosis. The interaction between subgroup and treatment was included in the Cox regression model to determine if the treatment effect differed by subgroup. The same subgroups analysed for the primary and secondary outcomes were also analysed with respect to colonoscopy results and CDEIS scores.

Publication policy

To safeguard the integrity of the trial, the primary results of the trial were published by the group as a whole in collaboration with local investigators, and local investigators were acknowledged.³⁰ The success of the trial was dependent on the collaboration of many people and, particularly, the local investigators. The results were, therefore, presented to the trial local investigators first.

Organisation

A TSC and a DMC were established. No formal charter was put in place, but both committees met formally every 6 months throughout the trial in accordance with Medical Research Council (MRC)/Efficacy and Mechanism Evaluation (EME) programme requirements following circulation of a standardised report. Day-to-day management of the trial was overseen by a TMG comprising the chief investigator, the principal investigator at the lead site in Edinburgh, the lead research nurse and the trial manager. Support from the Chief Scientist Officer enabled a dedicated specialist nurse to support the trial at the initial five Scottish sites. The local Comprehensive Local Research Networks supported research nursing time and employed or re-allocated a research nurse to support all aspects of the trial at sites across England and Wales.

Confidentiality

Patients were identified by their trial number to ensure confidentiality. Stringent precautions were taken to ensure confidentiality of names and addresses at ECTU and the sites. The chief investigator and local investigators ensured conservation of records in areas to which access is restricted.

Audit

A risk-based monitoring strategy was implemented for all participating sites with onsite monitoring conducted by either the sponsor's monitoring team or a member of the TMG at a selected number of sites depending on the issues identified at each site. Site visits were conducted during the course of the trial at University College Hospital, London, on 5 December 2012, Torbay Hospital, Torquay, on 6 November 2013, Ninewells Hospital, Dundee, on 12 March 2014, Aberdeen Royal Infirmary, Aberdeen, on 11 September 2015, Bristol Royal Infirmary, Bristol, on 30 September 2015 and St Marks Hospital, Harrow, on 7 October 2015. A central audit of trial management was conducted on 12 December 2012 at the central co-ordinating site at ECTU. In addition, an investigation was conducted by the sponsor following the lodging of a formal complaint to the Medicines and Healthcare products Regulatory Agency in July 2013 regarding the wording on an information newsletter sent to a site regarding withdrawal procedures. Recommendations were made following the investigation, but no evidence was found of improper conduct regarding withdrawal procedures.

Termination of the study

Before termination of recruitment, ECTU contacted all sites by telephone or e-mail in order to inform sites of the final date for recruitment. Once the recruitment period had expired, the internet-based randomisation database was disabled to prevent further recruitment. All recruited patients received trial medication for a maximum of 3 years (36 months) post randomisation. The final patient's final visit took place in April 2015 and the database was locked in June 2015. A declaration of the end of trial form was sent to the Multicentre Research Ethics Committee following the formal trial end date of 30 September 2015. The following documents were archived in each site file to be kept for at least 20 years in accordance with MRC policy: original consent forms, data forms, trial-related documents and correspondence. The trial master files at ECTU will be archived for at least 20 years.

Funding

The costs for the study itself were covered by a grant from the MRC. See the MRC/EME programme website for further project information.³¹ Additional support was provided by the Chief Scientist Officer.

Indemnity

If there was negligent harm during the clinical trial, then the NHS body owes a duty of care to the person harmed and NHS indemnity covered NHS staff, medical academic staff with honorary contracts and those conducting the trial. NHS indemnity did not offer no-fault compensation. The co-sponsors were responsible for ensuring that proper provision was made for insurance or indemnity to cover their liability and the liability of the chief investigator and staff.

Ethics approval and research governance

Ethics approval for the study was given by Scotland A Research Ethics Committee in August 2007 (reference number 07/MRE00/74). Local NHS management approval and appropriate site-specific assessments were obtained at each participating NHS trust. The trial was registered with the International Standard Randomised Controlled Trial Register under the reference number ISRCTN89489788 along with the European Clinical Trials Database under the reference number 2006-005800-15, and the UK Clinical Research Network Portfolio Database under the reference number 5813. A summary of the changes made to the original protocol is given in *Report Supplementary Material 3* and an overview of all participant information and consent forms is given in *Report Supplementary Material 4*.

Chapter 3 Results

Recruitment

Patients were recruited from the following dates: June 2008 to April 2012 (46 months). The addition of 24 sites in England and Wales was in response to slower than anticipated recruitment over the initial 24 months. Initial study recruitment projection figures were based on surgical data collected from the five original Scottish hospitals in the 5 years prior to the grant application. These data indicated that 60% of patients would proceed from surgery into the trial. In practice, the proportion of patients recruited into the trial following surgery at the initial five sites was 30% as a result of higher than expected contraindications to the trial entry and patients' greater than anticipated reluctance to receive placebo. An extension to the study recruitment period was granted in 2010, along with approval for the trial to be extended to additional centres across England and Wales. The trial completed recruitment on target according to the revised schedule on 23 April 2012, with the final patient's final visit completed on schedule in April 2015.

Participant flow

A Consolidated Standards of Reporting Trials (CONSORT) diagram for recruitment is provided in *Figure 1*. In total, 328 patients were screened and 240 were randomised, thereby meeting and slightly exceeding the recruitment target of 234. Seventy-eight per cent of eligible patients were randomised to the study following screening, with 22% of patients declining to take part.




FIGURE 1 The CONSORT diagram for TOPPIC.

All 240 randomised patients were analysed. A total of 128 (53%) participants were randomised to receive MP and 112 (47%) to placebo. All randomised patients received at least one dose of study drug. A protocol violation was recorded involving a participant who was prescribed a study drug from the wrong treatment arm 6 weeks post randomisation; the error was reported and the correct study drug issued.

Summary of ineligible and non-recruited patients

Table 3 summarises the number of ineligible and non-recruited patients at the participating centres. Five centres did not randomise any patients during the recruitment period and were closed early.

TABLE 3 Ineligible and non-recruited patients across participating centres

Centre number	Centre name	Pre-screening ineligible	Number of candidates	Number randomised	Number of ineligible	Number of non-recruits
11	Edinburgh	150	91	78 ^a	1	14
12	Aberdeen	62	23	17	1	4
13	Dundee	49	29	21	2	6
14	Glasgow Stobhill	15	25	19	3	3
15	Glasgow Royal Infirmary	29	15	8	1	6
16	Exeter	25	28	11	0	17
17	Coventry	15	6	6	0	0
18	Liverpool	25	14	8	2	3
19	Manchester	20	5	3	0	2
20	Bristol	3	6	5	0	1
21	UCLH	59	7	5	0	2
24	Oxford	32	12	9	2	1
25	Salford	31	4	2	1	1
26	Swansea	11	6	4	1	1
27	Royal Free	14	2	2	0	0
28	Barts	24	1	1	0	0
29	Torbay	11	6	6	0	0
30	Norfolk & Norwich	0	1	0	0	1
31	Stockton	4	1	0	0	1
32	Southampton	18	4	2	1	1
33	Plymouth	20	3	3	0	0
34	Durham	34	8	6 ^b	1	2
35	Hull	22	3	3	0	0
36	Leeds	36	10	8	1	1
38	Wolverhampton	36	0	0	0	0
39	North Staffordshire	0	2	1	0	1
40	Nottingham	15	2	2	0	0

TABLE 3 Ineligible and non-recruited patients across participating centres (*continued*)

Centre number	Centre name	Pre-screening ineligible	Number of candidates	Number randomised	Number of ineligible	Number of non-recruits
42	St Marks	14	1	1	0	0
43	Rotherham	20	5	4	0	0
44	Birmingham Queen Elizabeth	0	3	2	1	0
45	Inverness	2	1	1	0	0
46	Darlington	14	4	2	2	0
47	Bradford	5	1	0	0	1
48	Birmingham City	11	0	0	0	0

UCLH, University College London Hospital.

a Two participants at Edinburgh transferred from other sites (Aberdeen and Liverpool).

b One participant at Rotherham transferred from another site (Durham).

Characteristics used for stratification of randomisation

Randomised patients were stratified according to centre and smoking status (31 blocks in total). *Table 4* shows the numbers of patients randomised per recruiting centre, with the Edinburgh site recruiting the highest proportion of patients (32.5%). Smoking status (defined as those patients smoking more than one cigarette per day) is shown in *Table 5*.

Characteristics at pre-assessment

Characteristics of randomised patients at pre-assessment are shown in *Table 6*. The group randomised to MP had slightly more patients who had previously been treated with MP, azathioprine and immunosuppressant agents, although all other demographics and characteristics were similar.

Patient characteristics at randomisation

Table 7 shows the baseline characteristics of participants at randomisation (week 0). The two treatment groups were similar across the variables assessed, which included weight, faecal calprotectin levels, and CDAI or IBDQ scores.

Adherence to trial protocol

Adherence to trial medication

A summary of the duration of trial medication is shown in *Table 8*, with *Figure 2* showing a Kaplan–Meier plot of the duration of medication in years. The reasons for non-completion of the full treatment period are detailed in *Table 9*. One hundred and thirty-six patients (56.7%) did not complete 3 years of trial medication, with 80 (58.8%) patients not completing as the result of adverse events, 21 (15.4%) because of early withdrawal, 18 (13.2%) because of abnormal safety blood results, 16 (11.8%) being lost to follow-up and one (0.7%) patient dying.

TABLE 4 Number of patients randomised at each recruiting centre

Centre name	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Edinburgh	38 (29.7)	40 (35.7)	78 (32.5)
Aberdeen	9 (7.0)	8 (7.1)	17 (7.1)
Dundee	11 (8.6)	10 (8.9)	21 (8.8)
Glasgow Stobhill	10 (7.8)	9 (8.0)	19 (7.9)
Glasgow Royal Infirmary	5 (3.9)	3 (2.7)	8 (3.3)
Exeter	6 (4.7)	5 (4.5)	11 (4.6)
Coventry	3 (2.3)	3 (2.7)	6 (2.5)
Liverpool	6 (4.7)	2 (1.8)	8 (3.3)
Manchester	2 (1.6)	1 (0.9)	3 (1.3)
Bristol	2 (1.6)	3 (2.7)	5 (2.1)
UCLH	3 (2.3)	2 (1.8)	5 (2.1)
Oxford	5 (3.9)	4 (3.6)	9 (3.8)
Salford	2 (1.6)	0 (0.0)	2 (0.8)
Swansea	3 (2.3)	1 (0.9)	4 (1.7)
Royal Free	1 (0.8)	1 (0.9)	2 (0.8)
Barts	1 (0.8)	0 (0.0)	1 (0.4)
Torbay	4 (3.1)	2 (1.8)	6 (2.5)
Southampton	1 (0.8)	1 (0.9)	2 (0.8)
Plymouth	2 (1.6)	1 (0.9)	3 (1.3)
Durham	3 (2.3)	3 (2.7)	6 (2.5)
Hull	1 (0.8)	2 (1.8)	3 (1.3)
Leeds	4 (3.1)	4 (3.6)	8 (3.3)
North Staffordshire	1 (0.8)	4 (3.6)	8 (3.3)
Nottingham	1 (0.8)	1 (0.9)	2 (0.8)
St Marks	0 (0.0)	1 (0.9)	2 (0.8)
Rotherham	2 (1.6)	2 (1.8)	4 (1.7)
Birmingham Queen Elizabeth	0 (0.0)	2 (1.8)	2 (0.8)
Inverness	1 (0.8)	0 (0.0)	1 (0.4)
Darlington	1 (0.8)	1 (0.9)	2 (0.8)

UCLH, University College London Hospital.

TABLE 5 Smoking status of randomised patients

Smoking status	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Smoker	29 (22.7)	26 (23.2)	55 (22.9)
Non-smoker	99 (77.3)	86 (76.8)	185 (77.1)

TABLE 6 Patient characteristics at pre-assessment

Patient characteristic	Treatment, n (%)		Overall (N = 240), n (%)
	MP (N = 128)	Placebo (N = 112)	
Sex			
Female	79 (61.7)	67 (59.8)	146 (60.8)
Male	49 (38.3)	45 (40.2)	94 (39.2)
Previous treatment with MP			
Yes	14 (10.9)	5 (4.5)	19 (7.9)
No	114 (89.1)	106 (94.6)	220 (91.7)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
Previous treatment with azathioprine			
Yes	80 (62.5)	47 (42.0)	127 (52.9)
No	48 (37.5)	64 (57.1)	112 (46.7)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
Previous treatment with infliximab			
Yes	21 (16.4)	15 (13.4)	36 (15.0)
No	104 (81.3)	96 (85.7)	200 (83.3)
Missing	3 (2.3)	1 (0.9)	4 (1.7)
Previous treatment with methotrexate			
Yes	8 (6.3)	7 (6.3)	15 (6.3)
No	120 (93.8)	104 (92.9)	224 (93.3)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
Previous treatment with other corticosteroids			
Yes	97 (75.8)	79 (70.5)	176 (73.3)
No	31 (24.2)	32 (28.6)	63 (26.3)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
Any previous immunosuppressants			
Yes	112 (87.5)	86 (76.8)	198 (82.5)
No	16 (12.5)	25 (22.3)	41 (17.1)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
CD location			
Ileal	54 (42.2)	39 (34.8)	93 (38.8)
Colonic	4 (3.1)	2 (1.8)	6 (2.5)
Ileocolonic	70 (54.7)	70 (62.5)	140 (58.3)
Missing	0 (0.0)	1 (0.9)	1 (0.4)

continued

TABLE 6 Patient characteristics at pre-assessment (continued)

Patient characteristic	Treatment, n (%)		Overall (N = 240), n (%)
	MP (N = 128)	Placebo (N = 112)	
CD type			
Non-stricturing non-penetrating	50 (39.1)	45 (40.2)	95 (39.6)
Stricturing	63 (49.2)	46 (41.1)	109 (45.4)
Penetrating	15 (11.7)	19 (17.0)	34 (14.2)
Missing	0 (0.0)	2 (1.8)	2 (0.8)
Previous surgery			
Yes	46 (35.9)	28 (25.0)	74 (30.8)
No	82 (64.1)	83 (74.1)	165 (68.8)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
TPMT			
Normal	116 (90.6)	96 (85.7)	212 (88.3)
Heterozygous	12 (9.4)	16 (14.3)	28 (11.7)
Age at diagnosis (years)			
≤ 40	103 (80.5)	87 (77.7)	190 (79.2)
> 40	25 (19.5)	23 (20.5)	48 (20.0)
Unknown	0 (0.0)	2 (1.8)	2 (0.8)
Duration of CD (years)			
≤ 1	37 (28.9)	41 (36.6)	78 (32.5)
> 1	91 (71.1)	69 (61.6)	160 (66.7)
Unknown	0 (0.0)	2 (1.8)	2 (0.8)
Age (years)			
Mean	39.2	38.2	38.7
Median	38.0	36.0	38.0
SD	12.8	13.4	13.1
Q1, Q3	28, 50	28, 48	28, 48
Min., max.	17, 67	17, 75	17, 75
n (missing)	128 (0)	112 (0)	240 (0)
Duration of CD (years)			
Mean	7.7	7.6	7.6
Median	3.0	4.0	3.0
SD	9.7	9.5	9.6
Q1, Q3	0, 11	0, 11	0, 11
Min., max.	0, 39	0, 47	0, 47
n (missing)	128 (0)	110 (2)	238 (2)

max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.

TABLE 7 Patient characteristics at randomisation

Patient characteristic	Treatment		
	MP (N = 128)	Placebo (N = 112)	Overall (N = 240)
Weight (kg)			
Mean	70.7	70.7	70.7
Median	69.9	68.8	69.4
SD	14.4	13.7	14.0
Q1, Q3	58.5, 80.1	62.0, 76.8	60.0, 78.1
Min., max.	44.3, 111.9	43.6, 123.8	43.6, 123.8
n (missing)	128 (0)	112 (0)	240 (0)
Height (cm)			
Mean	168	169	169
Median	168	168	168
SD	9	9	9
Q1, Q3	161, 175	162, 177	161, 176
Min., max.	149, 193	150, 193	149, 193
n (missing)	128 (0)	112 (0)	240 (0)
Faecal calprotectin ($\mu\text{g/g}$ of faeces)			
Mean	124.4	160.1	141.2
Median	80.0	77.5	80.0
SD	170.9	213.9	192.7
Q1, Q3	30, 125	40, 165	40, 140
Min., max.	0, 920	0, 1040	0, 1040
n (missing)	108 (20)	96 (16)	204 (36)
Neutrophil count ($10^9/\text{l}$)			
Mean	4.45	4.22	4.34
Median	4.20	3.88	4.10
SD	1.76	1.63	1.70
Q1, Q3	3.4, 5.2	3.0, 5.0	3.2, 5.1
Min., max.	1.5, 13.8	1.7, 8.9	1.5, 13.8
n (missing)	127 (1)	111 (1)	238 (2)
CDAI score			
Mean	130	121	125
Median	111	112	112
SD	86	72	80
Q1, Q3	63, 179	63, 161	63, 169
Min., max.	2, 459	5, 368	2, 459
n (missing)	128 (0)	112 (0)	240 (0)

continued

TABLE 7 Patient characteristics at randomisation (continued)

Patient characteristic	Treatment		Overall (N = 240)
	MP (N = 128)	Placebo (N = 112)	
IBDQ: overall average			
Mean	5.19	5.31	5.24
Median	5.38	5.56	5.47
SD	0.99	0.94	0.97
Q1, Q3	4.4, 5.9	4.9, 6.0	4.7, 6.0
Min., max.	1.9, 7.0	2.7, 6.7	1.9, 7.0
n (missing)	128 (0)	111 (1)	239 (1)
IBDQ: overall total			
Mean	166	170	168
Median	172	178	175
SD	32	30	31
Q1, Q3	142, 188	156, 191	150, 191
Min., max.	61, 223	85, 215	61, 223
n (missing)	128 (0)	111 (1)	239 (1)
SF-36: physical component score			
Mean	44.2	42.6	43.5
Median	45.0	43.2	44.5
SD	9.4	10.5	9.9
Q1, Q3	37, 52	36, 51	36, 52
Min., max.	22, 60	6, 60	6, 60
n (missing)	124 (4)	110 (2)	234 (6)
SF-36: mental component score			
Mean	45.3	46.4	45.8
Median	47.0	49.7	47.7
SD	11.9	12.5	12.3
Q1, Q3	38, 55	39, 56	38, 56
Min., max.	13, 66	15, 69	13, 69
n (missing)	124 (4)	110 (2)	234 (6)
EQ-5D: mobility, n (%)			
I have no problems in walking about	107 (83.6)	87 (77.7)	194 (80.8)
I have some problems in walking about	21 (16.4)	24 (21.4)	45 (18.8)
I am confined to bed	0 (0.0)	0 (0.0)	0 (0.0)
Missing	0 (0.0)	1 (0.9)	1 (0.4)

TABLE 7 Patient characteristics at randomisation (*continued*)

Patient characteristic	Treatment		Overall (N = 240)
	MP (N = 128)	Placebo (N = 112)	
EQ-5D: self-care, n (%)			
I have no problems with self-care	125 (97.7)	104 (92.9)	229 (95.4)
I have some problems washing or dressing myself	3 (2.3)	7 (6.3)	10 (4.2)
I am unable to wash or dress myself	0 (0.0)	0 (0.0)	0 (0.0)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
EQ-5D: usual activities, n (%)			
I have no problems	75 (58.6)	61 (54.4)	136 (56.7)
I have some problems	47 (36.7)	41 (36.6)	88 (36.7)
I am unable to perform my usual activities	6 (4.7)	9 (8.0)	15 (6.3)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
EQ-5D: pain/discomfort, n (%)			
I have no pain or discomfort	64 (50.0)	56 (50.0)	120 (50.0)
I have moderate pain or discomfort	61 (47.7)	54 (48.2)	115 (47.9)
I have extreme pain or discomfort	3 (2.3)	1 (0.9)	4 (1.7)
Missing	0 (0.0)	1 (0.9)	1 (0.4)
EQ-5D: anxiety/depression, n (%)			
I am not anxious or depressed	93 (72.7)	74 (66.1)	167 (69.6)
I am moderately anxious or depressed	33 (25.8)	34 (30.4)	67 (27.9)
I am extremely anxious or depressed	2 (1.6)	3 (2.7)	5 (2.1)
Missing	0 (0.0)	1 (0.9)	1 (0.4)

max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation; SF-36, 36-Item Short Form Health Survey.

TABLE 8 Duration of trial medication

Duration of trial medication (years)	Treatment, n (%)		Overall (N = 240), n (%)
	MP (N = 128)	Placebo (N = 112)	
≥ 3	62 (48.4)	42 (37.5)	104 (43.3)
< 3	66 (51.6)	70 (62.5)	136 (56.7)




FIGURE 2 Kaplan–Meier plot showing duration of trial medication in years.

TABLE 9 Reasons for randomised patients not completing 3 years of trial medication

Reason	Treatment, n (%)		Overall (N = 240), n (%)
	MP (N = 128)	Placebo (N = 112)	
Adverse event	39 (59.1)	41 (58.6)	80 (58.8)
Blood test result	12 (18.2)	6 (8.6)	18 (13.2)
Early withdrawal	8 (12.1)	13 (18.6)	21 (15.4)
Deceased	0 (0.0)	1 (1.4)	1 (0.7)
Lost to follow-up	7 (10.6)	9 (12.9)	16 (11.8)

Dosage was adjusted throughout the trial in accordance with the protocol (see *Tables 1* and *2*). *Table 10* provides a summary of doses at first and final visits. *Table 11* summarises doses at final visit compared with dose first allocated. Only a small proportion of patients continued on the same dosage ($n = 63$, 26.3%) or at an increased dosage ($n = 13$, 5.4%); in the majority either the dose was decreased ($n = 68$, 28.3%) or the trial medication was stopped altogether ($n = 96$, 40.0%). The dosage was decreased in a higher proportion of patients in the MP group (39.1%) than in the placebo group (16.1%), whereas a higher proportion in the placebo group than in the MP group remained on the same dosage (37.5% compared with 16.4%, respectively) or stopped trial medication (42.9% compared with 37.5, respectively). The dose was increased in a small number of patients, but the proportion was marginally higher in the MP group than in the placebo group (7.0% compared with 3.6%).

Adherence to the trial visits and withdrawal

Table 12 shows the number of patients who reached the end of the study (week 157 post randomisation; $n = 161$, 67.1%). Seventy-nine patients did not reach the final study visit, with 52 withdrawn early at their own choice or by their clinician and a further 26 being lost to follow-up or non-attenders; there was one death.

TABLE 10 Summary of doses at first and final visit

Dosage	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Dose (mg) allocated at first visit			
50 alternate days	0 (0.0)	1 (0.9)	1 (0.4)
50 daily	17 (13.3)	17 (15.2)	34 (14.2)
50/100 alternate days	73 (57.0)	62 (55.4)	135 (56.3)
100 daily	34 (26.6)	27 (24.1)	61 (25.4)
150 daily	4 (3.1)	5 (4.5)	9 (3.8)
Dose allocated at final visit			
Stop	48 (37.5)	48 (42.9)	96 (40.0)
50 alternate days	17 (13.3)	5 (4.5)	22 (9.2)
50 daily	33 (25.8)	20 (17.9)	53 (22.1)
50/100 alternate days	17 (13.3)	25 (22.3)	42 (17.5)
100 daily	13 (10.2)	13 (11.6)	26 (10.8)
150 daily	0 (0.0)	1 (0.9)	1 (0.4)

TABLE 11 Summary of doses at final visit, compared with dose first allocated

Final dose change	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Dose decreased	50 (39.1)	18 (16.1)	68 (28.3)
Dose stayed the same	21 (16.4)	42 (37.5)	63 (26.3)
Dose increased	9 (7.0)	4 (3.6)	13 (5.4)
Trial medication stopped	48 (37.5)	48 (42.9)	96 (40.0)

TABLE 12 Summary of withdrawal at final study visit (week 157 post randomisation)

Parameter	Category	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
		MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Week 12 (week 157, <i>n</i> = 161)	Patient attended	89 (69.5)	72 (64.3)	161 (67.1)
	Patient did not attend	7 (5.5)	2 (1.8)	9 (3.8)
	Early withdrawal	24 (18.8)	26 (23.2)	50 (20.8)
	Withdrawn by clinician	1 (0.8)	1 (0.9)	2 (0.8)
	Lost to follow-up	7 (5.5)	10 (8.9)	17 (7.1)
	Deceased	0 (0.0)	1 (0.9)	1 (0.4)

The length of patient follow-up, in months, is shown in *Table 13*. The mean follow-up period was 28.6 months overall (maximum follow-up was 48 months), with a slightly longer follow-up in the MP group than in the placebo group (29.3 months vs. 27.8 months).

Adherence to study blinding

Treatment blinding was broken for 12 patients, and the reasons are listed in *Table 14*.

TABLE 13 Length of patient follow-up

Months	Treatment		Overall (N = 240)
	MP (N = 128)	Placebo (N = 112)	
Mean	29.3	27.8	28.6
Median	36.0	36.0	36.0
SD	12.2	12.2	12.2
Q1, Q3	28, 36	20, 36	23, 36
Min., max.	0, 48	0, 38	0, 48
n (missing)	128 (0)	112 (0)	240 (0)

max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.

TABLE 14 Emergency unblinding by treatment allocation with reasons

Patient ID	Centre	Date		Explanation
		Randomisation	Unblinding	
Treatment group				
<i>MP</i>				
11003	Edinburgh	13 June 2008	27 January 2009	Primary end point reached
11030	Edinburgh	3 November 2009	27 February 2014	Adverse event post trial
11064	Edinburgh	21 February 2011	5 April 2012	Other
<i>Placebo</i>				
11053	Edinburgh	18 August 2010	29 February 2012	Other
11078	Edinburgh	5 September 2011	31 May 2012	Other
11082	Edinburgh	13 September 2011	2 September 2013	Other
12002	Aberdeen	30 October 2008	3 February 2009	SUSAR
12014	Aberdeen	31 March 2010	17 May 2010	SUSAR
14010	Glasgow Stobhill	6 October 2009	26 October 2009	SUSAR
16004	Exeter	17 June 2010	25 November 2010	SUSAR
18007	Liverpool	3 May 2011	9 July 2013	SUSAR
44003	Birmingham Queen Elizabeth	16 January 2012	17 March 2015	Adverse event post trial

ID, identification; SUSAR, suspected unexpected serious adverse reaction.

Adherence to trial procedures

A total of nine protocol violations were recorded during the course of the study: five relating to study sample storage and four relating to study dosage and affecting specific sites and specific patients. A total of 216 deviations were recorded. The deviation categories are provided in *Table 15*.

Concomitant medication

Concomitant medications are shown in *Table 16*.

Outcomes and estimation

Primary outcome

The primary outcome was postoperative clinical recurrence of CD, defined as a CDAI score of > 150 points with an increase from baseline of 100 points, together with the need for anti-inflammatory rescue therapy or primary surgical intervention.

As shown in *Tables 17* and *18*, the primary outcome was reached by 42 patients (17.5%); 16 out of 128 (12.5%) on MP versus 26 out of 112 (23.2%) on placebo (HR 0.535, 95% CI 0.27 to 1.06; adjusted $p = 0.073$; HR 0.527, 95% CI 0.28 to 0.99; unadjusted $p = 0.046$). Of the 42 who reached the primary end point, 37 participants (88%) met the CDAI score trigger and had rescue therapy initiated, whereas five (12%) met the CDAI score trigger and had both rescue therapy and primary surgical intervention.

The HR of < 1 for both the adjusted and unadjusted analyses indicates a treatment effect in favour of MP. The associated confidence limits for the adjusted and unadjusted results demonstrate borderline statistical significance at the 5% level.

For the 42 patients who reached primary outcome, *Table 19* shows the follow-up and recurrence for the 26 (10.8%) participants reaching the primary outcome and completing the full 36-month follow-up, and for the 16 (6.7%) participants reaching the primary outcome with < 36 months of follow-up in the trial.

Secondary outcome: clinical recurrence

The secondary outcome of clinical recurrence was postoperative clinical recurrence of CD, defined as a CDAI score of > 150 points with an increase from baseline of 100 points, or the need for anti-inflammatory rescue therapy or primary surgical intervention.

TABLE 15 Protocol deviations by category

Protocol deviation	Overall (n)
Study visit missed or out of window	49
Safety bloods missed or out of window	89
Colonoscopy missed or out of window	22
Questionnaire missed or out of window	3
Calprotectin sample missed or out of window	25
Medication miscounted or taken incorrectly	11
TGN sample missed or out of window	3
Other	14

TABLE 16 Summary of concomitant medication

Parameter	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Concomitant medications taken?			
Yes	119 (93.0)	111 (99.1)	230 (95.8)
No	9 (7.0)	1 (0.9)	10 (4.2)
Total number of concomitant medications	1051	965	2016
Number of prohibited and non-prohibited medications			
Prohibited	93 (8.8)	126 (13.1)	219 (10.9)
Non-prohibited	958 (91.2)	839 (86.9)	1797 (89.1)
Number of occasions concomitant medications taken			
1	7 (5.9)	7 (6.3)	14 (6.1)
2	10 (8.4)	12 (10.8)	22 (9.6)
3	9 (7.6)	7 (6.3)	16 (7.0)
4	9 (7.6)	5 (4.5)	14 (6.1)
5	12 (10.1)	12 (10.8)	24 (10.4)
6–10	31 (26.1)	33 (29.7)	64 (27.8)
11–15	22 (18.5)	21 (18.9)	43 (18.7)
> 15	19 (16.0)	14 (12.6)	33 (14.3)
Requiring rescue therapy for CD?			
Yes	30 (25.2)	37 (33.3)	67 (29.1)
No	89 (74.8)	74 (66.7)	163 (70.9)
Number of occasions rescue therapy taken for CD			
1	10 (33.3)	10 (27.0)	20 (29.9)
2	3 (10.0)	11 (29.7)	14 (20.9)
3	8 (26.7)	6 (16.2)	14 (20.9)
4	4 (13.3)	4 (10.8)	8 (11.9)
5	1 (3.3)	2 (5.4)	3 (4.5)
> 5	4 (13.3)	4 (10.8)	8 (11.9)

TABLE 17 Summary of primary outcome

Primary outcome	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Primary outcome met?			
Yes	16 (12.5)	26 (23.2)	42 (17.5)
No	112 (87.5)	86 (76.8)	198 (82.5)

TABLE 18 Primary outcome statistical analysis (Cox proportional hazards model)

Analysis type	HR	95% CI level		$p > \chi^2$
		Lower	Upper	
Adjusted	0.535	0.27	1.06	0.073
Unadjusted	0.527	0.28	0.99	0.046

TABLE 19 Follow-up and recurrence

Follow-up and recurrence	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Follow-up of ≥ 3 years and primary outcome	11 (8.6)	15 (13.4)	26 (10.8)
Follow-up of < 3 years and primary outcome	5 (3.9)	11 (9.8)	16 (6.7)
Other	112 (87.5)	86 (76.8)	198 (82.5)

The secondary outcome events and statistical analysis are summarised in *Tables 20* and *21* respectively. The secondary outcome was reached by 74 (30.8%) patients: 34 out of 128 (26.6%) on MP versus 40 out of 112 (35.7%) on placebo (HR 0.737, 95% CI 0.44 to 1.23; adjusted $p = 0.243$; HR 0.746, 95% CI 0.47 to 1.18; unadjusted $p = 0.211$). Similar to the primary outcome, the HRs are in favour of MP, but the associated CIs indicate a lack of statistical significance.

Crohn's Disease Activity Index score

The mean score change from baseline in the CDAI for patients is shown in *Figure 3* from randomisation at visit 2 (week 0) to the final study visit at visit 12 (104 weeks post randomisation).

Secondary outcome: surgical intervention

Tables 22 and *23* present a summary of the patients who have had surgical intervention and the associated time (in days) to the intervention.

TABLE 20 Summary of secondary outcome events

Secondary outcome	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Secondary outcome met?			
Yes	34 (26.6)	40 (35.7)	74 (30.8)
No	94 (73.4)	72 (64.3)	166 (69.2)

TABLE 21 Secondary statistical analysis (Cox proportional hazards model)

Analysis type	HR	95% CI limit		$p > \chi^2$
		Lower	Upper	
Adjusted	0.737	0.44	1.23	0.243
Unadjusted	0.746	0.47	1.18	0.211

RESULTS




FIGURE 3 Mean change from baseline in CDAI scores per study visit.

TABLE 22 Surgical interventions: time to surgical intervention

Days	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Had surgical intervention?			
Yes	3 (2.3)	4 (3.6)	7 (2.9)
No	125 (97.7)	108 (96.4)	233 (97.1)
Number of occasions that surgery was undertaken			
1	2 (66.7)	4 (100)	6 (85.7)
2	1 (33.3)	0 (0.0)	1 (14.3)

TABLE 23 Surgical interventions: time (days) to surgical intervention

Time to surgical intervention (days)	Treatment		Overall (<i>N</i> = 240)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Mean	460.7	582.8	530.4
Median	629.0	581.0	629.0
SD	357.6	511.7	421.7
Q1, Q3	50, 703	149, 1017	60, 924
Min., max.	50, 703	60, 1109	50, 1109
<i>n</i> (missing)	3 (0)	4 (0)	7 (0)

max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.

i2: ≥ 5 aphthous lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis.

A small number of patients (7, 2.9%) had a secondary surgical intervention during the course of the trial, with similar numbers across the MP and placebo groups. The mean time to surgical intervention was 530.4 days, with a mean time being shorter in the MP group than in the placebo group (460.7 days vs. 582.8 days).

Secondary outcome: endoscopic recurrence

Tables 24 and 25 present a summary of endoscopic recurrence, as defined by Rutgeerts score, at visits 6 (week 49) and 12 (week 157), categorised by overall score and as either negative or positive. Figure 4 presents the number of negative and positive scores as bar charts.

Colonoscopy results (defined as negative or positive using the Rutgeerts score) are also summarised and the results of the statistical analysis of visit 12 colonoscopy results are presented in Table 26.

Comparing the incidence of positive colonoscopies at visit 12 for the MP group with the placebo group gave an adjusted odds ratio of 0.66 (95% CI 0.26 to 1.67; $p = 0.382$) and an unadjusted odds ratio of 0.79 (95% CI 0.39 to 1.61; $p = 0.516$), indicating no significant difference between treatment arms.

Endoscopic recurrence was also assessed using CDEIS score. Figure 5 shows CDEIS scores in a box plot, with a higher CDEIS score indicating greater severity of disease. The results of the statistical analysis are shown in Table 27, with an adjusted treatment effect of -0.612 (95% CI -1.92 to 0.69 ; $p = 0.354$), where an effect < 0 indicates a treatment effect in favour of MP. Higher CDEIS scores were recorded for the placebo group than for those patients allocated to MP at visits 6 and 12, although the difference was not statistically significant.

TABLE 24 Summary of colonoscopy results defined by Rutgeerts score and categorised by score


Time point	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Visit 6 (week 49, <i>n</i> = 208)			
i0: no lesions	33 (29.7)	14 (14.4)	47 (22.6)
i1: ≤ 5 aphthous ulcers	24 (21.6)	28 (28.9)	52 (25.0)
i2: > 5 aphthous ulcers	18 (16.2)	19 (19.6)	37 (17.8)
i3: diffuse aphthous ileitis	11 (9.9)	13 (13.4)	24 (11.5)
i4: diffuse ileal inflammation	5 (4.5)	3 (3.1)	8 (3.8)
Other	4 (3.6)	0 (0.0)	4 (1.9)
Missing	16 (14.4)	20 (20.6)	36 (17.3)
Visit 12 (week 157, <i>n</i> = 161)			
i0: no lesions	20 (22.5)	9 (12.5)	29 (18.0)
i1: ≤ 5 aphthous ulcers	18 (20.2)	20 (27.8)	38 (23.6)
i2: > 5 aphthous ulcers	18 (20.2)	11 (15.3)	29 (18.0)
i3: diffuse aphthous ileitis	4 (4.5)	5 (6.9)	9 (5.6)
i4: diffuse ileal inflammation	7 (7.9)	12 (16.7)	19 (11.8)
Other	2 (2.2)	2 (2.8)	4 (2.5)
Missing	20 (22.5)	13 (18.1)	33 (20.5)

Visit 6 was week 49 post randomisation and visit 12 was week 157 post randomisation.

TABLE 25 Summary of colonoscopy results defined by Rutgeerts score as either negative or positive

Time point	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Visit 6 (week 49, <i>n</i> = 208)			
Negative (< i2)	57 (51.4)	42 (43.3)	99 (47.6)
Positive (≥ i2)	34 (30.6)	35 (36.1)	69 (33.2)
Other	4 (3.6)	0 (0.0)	4 (1.9)
Missing	16 (14.4)	20 (20.6)	36 (17.3)
Visit 12 (week 157, <i>n</i> = 161)			
Negative (< i2)	38 (42.7)	29 (40.3)	67 (41.6)
Positive (≥ i2)	29 (32.6)	28 (38.9)	57 (35.4)
Other	2 (2.2)	2 (2.8)	4 (2.5)
Missing	20 (22.5)	13 (18.1)	33 (20.5)

Visit 6 was week 49 post randomisation and visit 12 was week 157 post randomisation.

**FIGURE 4** Colonoscopy by study visit (visit 6 was week 49 post randomisation and visit 12 was week 157 post randomisation). (a) Visit 6 and (b) visit 12.**TABLE 26** Visit 12 colonoscopy analysis results

Analysis type	Visit 12 odds ratio	95% CI limit		<i>p</i> -value
		Lower	Upper	
Adjusted	0.66	0.26	1.67	0.382
Unadjusted	0.79	0.39	1.61	0.516




FIGURE 5 Crohn's Disease Endoscopic Index of severity score by study visit (visit 6 was 49 weeks post randomisation and visit 12 was 157 weeks post randomisation). (a) Visit 6 and (b) visit 12. Mean CDEIS scores are indicated by a diamond in the box plot. The minimum is indicated by the bottom of the lower whisker, the maximum is indicated by the top of the upper whisker. The lower quartile is indicated by the horizontal line at the bottom of the box and the upper quartile is indicated by the horizontal line at the top of the box. Outliers are shown as small circles, identified as being 1.5 times outside the interquartile range. A higher CDEIS score indicates greater severity of the disease.

TABLE 27 Visit 12 treatment effect for CDEIS score

Analysis type	Visit 12 treatment effect	95% CI limit		p-value
		Lower	Upper	
Adjusted	-0.612	-1.92	0.69	0.354
Unadjusted	-0.661	-1.89	0.57	0.289

The adjusted analysis takes into account the stratification variables centre and smoking status, and also adjusts for previous treatment with MP or azathioprine. The visit 12 treatment effect compares MP with placebo (reference). An effect of < 0 indicates a treatment effect in favour of MP.

Secondary outcome: faecal calprotectin levels

Faecal calprotectin results were summarised by time and treatment group both as a continuous measure and categorically. The continuous change from baseline to each time point was also summarised and is presented in *Figure 6*, indicating an increase from baseline across all visits in the placebo group, in contrast to a decrease from baseline across all visits in the MP group. *Figure 7* shows a categorical summary of faecal calprotectin levels, indicating the proportions in both MP and placebo groups.

Faecal calprotectin levels were also assessed as a non-invasive marker of clinical recurrence of CD by incorporating it as a time-varying covariate in the Cox proportional hazards model. *Tables 28* and *29* summarise faecal calprotectin levels by colonoscopy result at visits 6 and 12. The results of the statistical analysis are presented in *Table 30* and indicate that faecal calprotectin levels are a significant predictor of the primary outcome. For each 100 µg/g increase in faecal calprotectin, the probability of reaching the primary outcome increased by 17.7%. These results should, however, be treated with caution as only 31 out of 42 events have been included in this analysis as a result of missing data.




FIGURE 6 Mean change from baseline in faecal calprotectin level. Faecal calprotectin results of <math>< 20\mu\text{g/g}</math> faeces have been included in the summary with a value of 0.




FIGURE 7 Categorical summary of faecal calprotectin levels (µg/g) in faeces. (a) MP group and (b) placebo group. Percentages are determined on non-missing data only.

TABLE 28 Faecal calprotectin levels by colonoscopy result at visit 6

Colonoscopy result	Treatment		Overall (N = 240)
	MP (N = 128)	Placebo (N = 112)	
Negative (< i2) (n = 99, 47.6%)			
Mean	98	181	133
Median	45	110	60
SD	148	243	197
Q1, Q3	20, 90	30, 180	20, 130
Min., max.	20, 810	20, 1080	20, 1080
n (missing)	44 (13)	33 (9)	77 (22)
Positive (≥ i2) (n = 57, 35.4%)			
Mean	240	353	291
Median	170	220	170
SD	305	308	308
Q1, Q3	50, 260	120, 590	90, 350
Min., max.	20, 1200	20, 1130	20, 1200
n (missing)	27 (7)	22 (13)	49 (20)

max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.

TABLE 29 Faecal calprotectin levels by colonoscopy result at visit 12

Colonoscopy result	Treatment		Overall (N = 240)
	MP (N = 128)	Placebo (N = 112)	
Negative (< i2) (n = 99, 47.6%)			
Mean	141	133	137
Median	45	70	60
SD	174	170	170
Q1, Q3	20, 260	20, 200	20, 200
Min., max.	20, 660	20, 750	20, 750
n (missing)	24 (14)	23 (6)	47 (20)
Positive (≥ i2) (n = 57, 35.4%)			
Mean	146	262	200
Median	110	200	140
SD	143	203	181
Q1, Q3	50, 180	130, 270	80, 240
Min., max.	20, 530	30, 750	20, 750
n (missing)	22 (7)	19 (9)	41 (16)

max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.
i2: ≥ 5 aphthous lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis.

TABLE 30 Analysis of faecal calprotectin as a time-varying covariate (Cox proportional hazards model)

Model	HR	95% CI limit		$p > \chi^2$	Number of primary events
		Lower	Upper		
100-unit change in calprotectin	1.177	1.082	1.282	0.0002	31

For each 100 µg/g increase in faecal calprotectin, the probability of reaching the primary outcome increases by 17.7%.

Secondary outcome: thioguanine nucleotide concentration levels


Thioguanine levels were summarised by time and treatment group both as a continuous measure and categorically following independent blind review. *Figure 8* shows the mean change from baseline in TGN levels, with a slight and unexplained rise in TGN levels in the placebo arm. *Figure 9* presents a categorical summary of TGN levels in the MP group at each of the five time points measured throughout the trial.

In a similar manner to faecal calprotectin levels, TGN was assessed as a non-invasive marker of clinical recurrence of CD by incorporating results from MP patients only as a time-varying covariate in the Cox proportional hazards model. As shown in *Table 31*, the corresponding time-varying covariate analysis of TGN concentrations (data available for 14 of the 16 patients receiving MP only) indicated that, for every 100-pmol/8 × 10⁸ red blood cell increase in TGN, the hazard of reaching the primary out come decreased by 20% (HR 0.800, 95% CI 0.565 to 1.132; $p = 0.207$).

Secondary outcome: changes in self-rated quality-of-life scores

Patient-reported outcome measures (as measured by IBDQ) were summarised at each visit based on observed scores and change from baseline scores for each of the four IBDQ subscales (bowel symptoms, emotional health, systemic systems and social function). Averages and totals across all subscales were summarised similarly.

In addition, the overall average IBDQ score and overall total IBDQ score were statistically analysed using a repeated measures analysis of covariance, modelling change from baseline, fitting terms for treatment, visit and the interaction between treatment and time.

**FIGURE 8** Mean change from baseline in TGN levels. RBC, red blood cell.




FIGURE 9 Categorical summary of TGN levels (pmol/8 × 10⁸ red blood cells). Percentages are determined on non-missing data only. RBC, red blood cell.

TABLE 31 Analysis of TGN as a time-varying covariate (patients receiving MP only) (Cox proportional hazards model)

Model	HR	95% CI limit		$p > \chi^2$	Number of primary events
		Lower	Upper		
100-pmol/8 × 10 ⁸ red blood cells change in TGN	0.800	0.565	1.132	0.207	14

For each 100-pmol/8 × 10⁸ red blood cells increase in TGN, the probability of reaching the primary outcome decreased by 20.0%. Fourteen out of 16 events have been included in this analysis, based on those patients receiving MP only.

For both the overall average and overall total, there were no significant differences between treatment and placebo groups across all study visits and the study overall. However, both treatment groups showed an improvement in quality of life across all study visits in comparison with baseline, with the MP group demonstrating the greater change across all visits. *Figures 10 and 11* depict the results of the statistical analysis for the overall average IBDQ and overall total IBDQ, respectively.

Safety outcomes

Adverse events

Of 1747 reported adverse events, 355 (20.3%) were infections, although only seven (0.4%) necessitated hospitalisation, with higher rates in the group allocated to placebo. The majority of adverse events were classed as either mild or moderate in severity [868 (91.6%) in the MP group and 728 (91.1%) in the placebo group]. Adverse events caused discontinuation of treatment in 80 patients overall (33%): 39 of the 128 (30%) patients in the MP group versus 41 of the 112 (36.6%) patients in the placebo group.




FIGURE 10 Change from baseline final model treatment effects and 95% CIs for overall average IBDQ.




FIGURE 11 Change from baseline final model treatment effects and 95% CIs for overall total IBDQ.

Adverse events in the trial cohort overall are shown in *Table 32*, with serious adverse events in *Table 33*. There were two cases of pancreatitis (0.1%, one in the MP group and one in the placebo group) and four malignancies (0.2%, three in the MP group and one in the placebo group): basal cell carcinoma, breast cancer and two cases of lentigo maligna. One participant died of coronary heart disease in the placebo group.

Deaths

One death was recorded during the study period (coronary heart disease). This was in the placebo group and was considered unrelated to the study intervention.

TABLE 32 Summary of reported adverse events

Parameter	Treatment, <i>n</i> (%)		Overall (<i>N</i> = 240), <i>n</i> (%)
	MP (<i>N</i> = 128)	Placebo (<i>N</i> = 112)	
Had adverse event			
Yes	121 (94.5)	105 (93.8)	226 (94.2)
No	7 (5.5)	7 (6.3)	14 (5.8)
Severity of worst event			
Mild	14 (11.6)	8 (7.6)	22 (9.7)
Moderate	65 (53.7)	59 (56.2)	124 (54.9)
Severe	41 (33.9)	38 (36.2)	79 (35.0)
Missing	1 (0.8)	0 (0.0)	1 (0.4)
Total number of adverse events	948	799	1747
All adverse events split by category			
Uncoded	1 (0.1)	1 (0.1)	2 (0.1)
GI symptoms: nausea/vomiting	78 (8.2)	41 (5.1)	119 (6.8)
GI symptoms: abdominal pain	132 (13.9)	141 (17.6)	273 (15.6)
GI symptoms: constipation/diarrhoea	54 (5.7)	56 (7.0)	110 (6.3)
GI symptoms: other	53 (5.6)	40 (5.0)	93 (5.3)
Worsening CD	41 (4.3)	37 (4.6)	78 (4.5)
Rash	35 (3.7)	17 (2.1)	52 (3.0)
Headache	61 (6.4)	38 (4.8)	99 (5.7)
Infections	171 (18.0)	184 (23.0)	355 (20.3)
Pain	30 (3.2)	19 (2.4)	49 (2.8)
Cancers	3 (0.3)	1 (0.1)	4 (0.2)
Deranged LFT	4 (0.4)	5 (0.6)	9 (0.5)
Pancreatitis	1 (0.1)	1 (0.1)	2 (0.1)
Joint pain/arthritis	72 (7.6)	65 (8.1)	137 (7.8)
Other	212 (22.4)	153 (19.1)	365 (20.9)

GI, gastrointestinal; LFT, liver function test.

Pregnancy

Of the 240 randomised patients, 14 pregnancies were reported (*Table 34*) during the course of the trial [nine female patients (one of whom had two pregnancies) and in the partners of four male patients] with 12 normal children and maternal outcomes. We observed one spontaneous abortion at approximately 21 weeks' gestation and one congenital anomaly (heart murmur, septal defect and hydrocephalus) in the infant of a patient in the placebo group.

Safety blood monitoring

Blood safety monitoring tests of interest were summarised by treatment and visit. Abnormal laboratory results outside the normal reference range were also summarised and are presented for each visit in *Table 35*. The numbers highlighted in italics indicate a higher value than in the other treatment group.

TABLE 33 Summary of reported serious adverse events

System Organ Class (SOC1)	Treatment, number of						Overall, number of		
	MP			Placebo					
	Patients	Events	Related events	Patients	Events	Related events	Patients	Events	Related events
Cardiac disorders	3	3	0	2	2	0	5	5	0
Congenital, familial and genetic disorders	0	0	0	1	1	1	1	1	1
Eye disorders	0	0	0	1	1	1	1	1	1
GI disorders	23	26	2	29	33	4	52	59	6
General disorders and administration site conditions	1	1	0	1	1	0	2	2	0
Hepatobiliary disorders	1	1	1	1	1	0	2	2	1
Infections and infestations	4	7	0	3	3	1	7	10	1
Injury, poisoning and procedural complications	1	1	0	1	1	0	2	2	0
Neoplasms benign, malignant and unspecified (including cysts and polyps)	1	1	0	1	1	0	2	2	0
Nervous system disorders	0	0	0	1	1	0	1	1	0
Renal and urinary disorders	4	6	0	2	2	0	6	8	0
Reproductive system and breast disorders	2	2	0	0	0	0	2	2	0
Skin and subcutaneous tissue disorders	1	1	0	1	2	1	2	3	1
Surgical and medical procedures	9	9	0	5	5	0	14	14	0
Vascular disorders	1	1	0	0	0	0	1	1	0
Total	51	59	3	49	54	8	100	113	11

GI, gastrointestinal.

TABLE 34 Reported pregnancies

Patient ID	Centre	Treatment	Sex	Estimated date of delivery	Delivery date	Maternal outcome	Child outcome
11008	Edinburgh	MP	Male ^a	26 July 2009	Unknown	Unknown	Normal
11012	Edinburgh	Placebo	Male ^a	11 August 2010	21 August 2012	Normal	Normal
11047	Edinburgh	MP	Female	12 November 2013	4 November 2013	Unknown	Normal
11054	Edinburgh	MP	Female	17 June 2012	30 May 2012	Caesarean	Normal
11067	Edinburgh	MP	Female	16 March 2012	5 March 2012	Caesarean	Normal
11075	Edinburgh	Placebo	Female	29 March 2013	13 March 2013	Induced (IUGR)	Normal
11075	Edinburgh	Placebo	Female	3 May 2014	7 April 2014	Normal	Normal
12017	Aberdeen	MP	Female	22 April 2013	Unknown	Abortion – spontaneous 5 October 2012	N/A
13024	Dundee	Placebo	Female	22 February 2012	22 February 2012	Normal	Normal
14010	Glasgow Stobhill	Placebo	Female	15 October 2010	22 October 2010	Forceps/ventouse	Normal
14024 ^b	Glasgow Stobhill	MP	Male ^a	Unknown	28 September 2015	Normal	Normal
15015	Glasgow Royal Infirmary	MP	Female	12 June 2013	31 May 2013	Normal	Normal
18007	Liverpool	Placebo	Female	11 October 2012	26 September 2012	Normal	Abnormal
34005	Durham	MP	Male ^a	Unknown	3 December 2012	Normal	Normal

ID, identifier; IUGR, intrauterine growth restriction; N/A, not applicable.

a Pregnancy in partner of male patient.

b Pregnancy reported following formal database lock.

TABLE 35 Blood safety monitoring: % of out of range values by visit and treatment group

Visit	Blood safety monitoring test															
	ALT		ALP		Albumin		C-reactive protein		WBC count		Haemoglobin		Neutrophils		Lymphocytes	
	MP	Placebo	MP	Placebo	MP	Placebo	MP	Placebo	MP	Placebo	MP	Placebo	MP	Placebo	MP	Placebo
2	21.9	8	9	<i>11.4</i>	4.7	<i>5.4</i>	21.9	20.5	8.6	8.9	48.4	42.9	7.0	5.4	37.5	35.7
3	24.2	6.5	6.6	<i>13.1</i>	2.4	<i>7.4</i>	26.8	29.6	<i>17.1</i>	9.3	42.3	28.7	5.7	6.5	49.6	42.6
4	<i>17.1</i>	5.6	6.2	8.9	8.5	5.6	18.8	<i>27.1</i>	<i>13.7</i>	8.4	26.5	23.4	4.3	3.7	47.9	31.8
5	<i>16.7</i>	11.1	4.5	4.3	6.1	6.1	12.3	23.2	7.9	5.1	22.8	26.3	6.1	5.1	50.9	30.3
6	<i>13.5</i>	7.2	6.5	4.4	3.6	<i>7.2</i>	15.3	<i>21.6</i>	5.4	<i>7.2</i>	17.1	<i>23.7</i>	2.7	6.2	<i>51.4</i>	25.8
7	<i>17.0</i>	9.2	2.9	3.8	2.8	<i>5.7</i>	14.2	<i>18.4</i>	9.4	8.0	13.2	<i>20.7</i>	4.7	5.7	<i>44.3</i>	19.5
8	<i>18.0</i>	7.2	3.1	<i>5.0</i>	3.0	<i>7.2</i>	15.0	<i>16.9</i>	<i>12.0</i>	7.2	13.0	22.9	8.0	7.2	<i>49.0</i>	19.3
9	<i>13.1</i>	3.8	2.1	0.0	4.0	<i>5.1</i>	10.1	<i>11.5</i>	5.1	7.7	14.1	<i>16.7</i>	6.1	6.4	<i>46.5</i>	19.2
10	<i>13.7</i>	6.8	1.1	<i>1.4</i>	4.2	<i>5.4</i>	<i>11.6</i>	10.8	<i>7.4</i>	6.8	6.3	<i>13.5</i>	3.2	0.0	36.8	18.9
11	9.9	2.8	1.1	<i>1.4</i>	2.2	<i>4.2</i>	7.7	<i>11.1</i>	4.4	2.8	8.8	<i>15.3</i>	2.2	1.4	46.2	15.3
12	<i>16.9</i>	5.6	2.3	1.4	3.4	<i>5.6</i>	9.0	5.6	4.5	2.8	7.9	8.3	2.2	1.4	<i>47.2</i>	15.3

ALP, alkaline phosphatase; ALT, alanine aminotransferase; WBC, white blood cell.
The numbers in italics indicate a higher value than the other treatment group.

Alanine aminotransferase and lymphocyte values were consistently higher across all visits in the MP group, whereas the majority of C-reactive protein values were higher in the placebo group. Albumin and haemoglobin values were higher in the placebo group from visits 6 and 5, respectively, until the end of the trial.

Prespecified subgroup analyses of primary and secondary outcomes

Subgroup analyses of the primary and secondary outcomes (clinical recurrence of CD) were analysed similarly to the main analysis of primary and secondary outcomes with the addition of an interaction term for treatment and subgroup in the Cox proportional hazards model.

Primary outcome

The results show that, in the entire study cohort, smokers had a higher chance of reaching the primary outcome than non-smokers [15/55 (27.3%) vs. 27/185 (14.6%); $p = 0.018$]. Among smokers, 3 out of 29 on MP (10.3%) had a clinical recurrence, compared with 12 out of 26 (46.2%) on placebo, demonstrating that MP was effective at preventing postoperative recurrence in smokers (unadjusted HR 0.127, 95% CI 0.04 to 0.46) but not in non-smokers (unadjusted HR 0.898, 95% CI 0.42 to 1.94). The number needed to treat was calculated as 3 in smokers and 31 in non-smokers. Other subgroup analyses assessing previous TPMT exposure, prior methotrexate use, prior infliximab use, previous surgery and age at diagnosis did not identify any differences between the groups.

Figure 12 shows the results of the overall unadjusted analysis of the primary outcome together with the results of the individual subgroup analyses.

Secondary outcome

Clinical recurrence

Similar to the subgroup analyses of the primary outcome, subgroup analyses for the secondary outcome demonstrated that smokers had a higher chance of reaching the secondary outcome than non-smokers [19/55 (34.5%) vs. 55/185 (29.7%); $p = 0.033$]. Among smokers, 6 out of 29 on MP (20.7%) had a secondary outcome, compared with 13 out of 26 (50.0%) on placebo, demonstrating that MP was effective at preventing postoperative recurrence in smokers (unadjusted HR 0.270, 95% CI 0.10 to 0.72) but not in non-smokers (unadjusted HR 0.995, 95% CI 0.58 to 1.70). There were no significant differences in the analyses of the other subgroups. *Figure 13* shows the results of the overall unadjusted analysis of the secondary outcome together with the results of the individual subgroup analyses.

Endoscopic recurrence

There were no significant differences in endoscopic recurrence, as defined by the Rutgeerts score, by treatment group on subgroup analyses except in the thiopurine-naive group (38 in the MP group vs. 29 in the placebo group; $p = 0.516$).

Figures 14 and *15* show the results of the overall unadjusted analysis of visit 12 colonoscopy results and CDEIS scores, together with the results of the individual subgroup analyses.




FIGURE 12 Forest plot of primary outcome (unadjusted). The subgroup *p*-values are from a test for an interaction between the treatment and subgroup variables.




FIGURE 13 Forest plot of secondary outcome (unadjusted). The subgroup *p*-values are from a test for an interaction between the treatment and subgroup variables.




FIGURE 14 Forest plot of colonoscopy results at visit 12 (unadjusted). The percentage of patients with a positive colonoscopy is based on positive ($\geq i2$) and negative ($< i2$) colonoscopy results only. Missing and other colonoscopy results have been excluded. The subgroup p -values are from a test for an interaction between the treatment and subgroup variables. $i2$: ≥ 5 aphthous lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis.




FIGURE 15 Forest plot of CDEIS score at visit 12 (unadjusted). The subgroup p-values are from a test for an interaction between the treatment and subgroup variables.

Chapter 4 Discussion

Context

This study is the largest randomised, double-blind study in postoperative CD reported to date. In the study cohort, analysed on an intention-to-treat basis, there is evidence of a reduction of clinical recurrence in patients on MP compared with placebo, although this finding was not statistically significant. It is notable that the treatment effect of 20% is lower than in previously conducted studies (Hanauer *et al.*:¹⁸ 40% reduction in mild CD lesions and 75% reduction in more severe lesions; Ardizzone *et al.*:¹⁹ 25% reduction). We judged a treatment effect of 20% appropriate because, given the side-effect profile of MP, it is arguable that a treatment effect of significantly < 20% is of limited clinical significance.

Endoscopic recurrence is an important secondary outcome that other studies have prioritised over clinical outcomes. No overall benefit of MP therapy on endoscopic outcome was identified in the present study using the prespecified criteria of a Rutgeerts score of \geq i2. However, on post hoc analysis, fewer patients on placebo than on MP had endoscopically normal appearances at the anastomosis. The endoscopic subgroup analysis showed an intriguing difference in treatment effect between thiopurine-naive and non-naive groups, with patients previously exposed to thiopurine having greatest evidence of benefit.

The apparent discrepancy between clinical outcome measures and endoscopic outcomes is noteworthy. There are several possible explanations for this, and clearly no consensus regarding whether or not to prioritise clinical outcomes over endoscopic outcomes has emerged from previous trial data. The stringency of our primary outcome and the internal correlation with faecal calprotectin assessment and with thiopurine metabolite concentrations are arguments in favour of prioritising and relying on the clinical primary outcome. Indeed, the validity and reproducibility of a Rutgeerts score of \geq i2 – defined in the primary study from Rutgeerts *et al.*,²⁶ but not subject to detailed replication as a predictor of clinical recurrence – has been debated.

With respect to clinical practice, the data emerging from the trial strongly highlight the importance of cigarette smoking in the pathogenesis and progression of CD, and as a target for therapeutic intervention. Not only do the data show that the effect of MP on primary outcome was of statistical as well as clinical significance in smokers, with a number needed to treat of only 3, but the analysis of factors predictive of primary outcome is also noteworthy. Only smoking habit was predictive of outcome, whereas age, sex or need for previous surgery were not implicated as risk factors for recurrence. The data underline the importance of smoking cessation in disease management, and prioritising this aspect using all available methodologies is of undeniable importance in clinical research. Previous studies have demonstrated that surgical recurrence increases with the number of cigarettes smoked each day, and that smoking cessation reduces clinical and surgical recurrence.^{32,33} To date, the constituents responsible in cigarette smoke, and pathogenic mechanisms involved in this association, have not been identified.

Limitations

The present study does have a number of limitations. There was a lower primary event rate than initially anticipated: the actual primary outcome rates in the treatment group were 12.5% in the MP group compared with 23.2% in the placebo group as opposed to expected rates of 30% and 50%. Of the 240 patients recruited into the study, 37 (15%) were also withdrawn or lost to follow-up. This compares favourably to the rates reported in earlier trials.^{10,18,19,34} In the present study, 80 (33%) patients discontinued therapy as a result of an adverse event [39 (30%) in the MP group vs. 41 (37%) in placebo group] and an additional 18 (8%) patients withdrew as a result of an abnormal blood test result picked up on safety monitoring [12 (9.4%) in

the MP group vs. 6 (5.4%) in the placebo group]. Ardizzone *et al.*¹⁹ reported treatment discontinuation rates attributable to adverse events of 15 (10.7%) in the azathioprine group and 6 (4%) in the mesalazine group, although figures on treatment discontinuation in other trials are more difficult to gauge from the published figures.

The number of discontinuations does raise questions in terms of adherence in routine clinical practice and, together with the numbers lost to follow-up, raises tantalising questions about the impact on the significance of the primary analysis. In this sense, however, the present study may reflect the real-life use of thiopurines in a postoperative population. We would argue that this trial has considerable value as a pragmatic trial in which the results and experiences of participating patients are highly generalisable to the clinic population seen not only in the UK but in much of Western Europe and North America.

Another limitation was the number of missing values in the analysis of the secondary outcomes, which could affect the overall results. However, the proportion of missing values between treatment groups was assessed and found to be similar.

There were no worrying signals with respect to adverse events in the present study. Indeed, lower than expected rates of pancreatitis and malignancies were reported. Fourteen pregnancies were reported, with 12 healthy births, one miscarriage and one abnormal birth to a mother in the placebo group. The stringent precautions for blood monitoring may well be pertinent to the safety profile demonstrated in the trial.

Strengths

The strengths of this study include the placebo arm, the assessment of both clinical and endoscopic outcomes, dose adjustment by TPMT status, the stringency of the primary end point and the attention to maintenance of blinding throughout, as well as its generalisability to routine clinical practice.

A further issue worthy of discussion and of exploration in further studies is whether or not a stronger treatment effect would have been seen if the TPMT metabolite profiles were available for dose adjustment during the trial, as is now routine in clinical practice. The data presented suggest that a significant proportion of patients may have benefited from higher doses of active drug; indeed, almost 60% had levels below the accepted lower limit of the therapeutic range.

Applicability in UK hospitals and beyond

The study population and the overall findings of the study are highly generalisable in clinical practice in the UK and indeed across Western Europe and North America.

Taken with other recent data from the POCER study investigators,¹³ the present study helps make progress towards a treatment algorithm in postoperative CD that may prove to be generalisable in clinical practice. We suggest that cessation of cigarette smoking emerges as the key intervention to emphasise ahead of drug therapy. In those who continue to smoke, but not non-smokers, thiopurine therapy appears to be justified in the early postoperative period, and we would now suggest the need to explore dose optimisation by metabolite testing. In thiopurine-intolerant patients, anti-TNF- α therapy may be justified. In all patients, reassessment of clinical status, endoscopic appearances and calprotectin levels in 6 months will determine need for escalation of therapy.

Reducing variance in clinical practice

The present study provides useful insights by identifying size of effect of thiopurine therapy overall, and the subgroup in which it is most effective. The identification of smoking habit as the key risk factor for recurrence is also of considerable importance in practice.

All these represent important points generalisable to clinical practice and intervention.

The present data are suggestive of utility of calprotectin levels in predicting clinical recurrence, and utility of metabolites in optimising thiopurine therapy. These data will need to be explored in further studies but both represent potential biomarkers that may help optimise intervention.

Potential risks not explored in this study

The study had a 3-year treatment period but did not have a follow-up period for recruited patients. The longer-term management of this patient population and the duration of therapy remain unexplored.

Unanticipated findings

The magnitude of effect of smoking habit on primary outcome was unexpected, and represents a key finding.

Patient public involvement

Patient public involvement in TOPPIC was limited. A lay representative formed part of the TSC and, as such, was invited to all formal meetings and provided with the TSC reports and updates with the initial meetings attended.

Chapter 5 Conclusions

Implications for health care

TOPPIC was designed in 2003–4 and completed in 2015 as the largest single study of the efficacy of MP in reducing postoperative recurrence in CD. This has since remained an important question in the context of disease management over time, although the introduction of new biological therapies and the widespread use of biomarkers and therapeutic drug monitoring need to be taken into account in assessing current impact and implications.

We have defined the rate of clinical and endoscopic disease recurrence in the UK population, and have characterised the key risk factor amenable to public health intervention as smoking, while also demonstrating that other proposed risk factors do not have a significant effect in this study. The last finding is not to be underestimated – age, disease behaviour and previous exposure to thiopurines do not appear to influence outcome adversely.

From the clinical perspective, the need to educate and re-educate patients and clinicians regarding the deleterious effects of smoking on outcome is critical, as is the need to put in place all available strategies to help with smoking cessation.

From the trial itself, MP was not effective in reducing the frequency of clinical postoperative recurrence of CD overall, but the data suggest that it has clinically meaningful effect among the subgroup of patients who continue to smoke after surgery. Importantly, with the benefit of the results of therapeutic drug monitoring of TPMT levels available after the trial, it appears that many patients were underdosed per protocol, and the data generated in the trial may underestimate the potential benefit in the clinic.

Taking these data in the context of other published data in this field, we suggest that risk stratification of relapse after surgery is principally influenced by smoking habit, and would offer prophylaxis with thiopurine therapy to those individuals who continue to smoke, if the drug is tolerated. In all patients, these data, and the data from the POCER study, make the case for monitoring faecal calprotectin levels and offering endoscopic assessment within 6–12 months of surgery to those with elevated calprotectin values, or clinical concern of recurrence. At this stage, the introduction of thiopurine therapy or biological therapy needs to be assessed in terms of the presence or absence of symptoms, and endoscopic features.

Recommendations for research

A number of areas in which further research is required emerge from the present study.

- Although the present study defines the role of MP in postoperative prevention, we also provide evidence that the effect might be underestimated in the present study.
- A further trial designed to incorporate concomitant real-time measurements of faecal calprotectin levels, TPMT metabolites and other biomarkers in the clinic, and using the combination of these parameters to optimise and target therapy on appropriate individuals, is likely to provide a more accurate estimate of the full therapeutic potential of thiopurines in the postoperative setting.
- Most importantly, there is a research need to explore the efficacy of other agents as monotherapy or co-therapy with thiopurines – anti-TNF- α therapies, vedolizumab and ustekinumab will all be available in this context in 2017, with other new oral agents in advanced stages of analysis. This area is likely to require specific trials, incorporating the understanding generated in the present study.

- The trial has also demonstrated the need for research to identify the optimum biologically meaningful outcome measure in studies of postoperative recurrence, with discrepancies between the results when clinical, biochemical and endoscopic end points are considered.
- With TOPPIC strongly highlighting the effect of smoking on recurrence rates, the data demonstrate the need for directed intervention studies to assess the relative success of alternative strategies in smoking cessation in patients with CD.
- The trial also highlights the need for mechanistic studies to explore the very well-documented association between smoking and development, with epigenetic, immune-mediated mechanisms currently of particular interest.
- Exploration of efficacy of other agents in preventing postoperative relapse – these will include anti-TNF- α therapies and anti-adhesion strategies.

Acknowledgements

Use of the IBDQ, authored by Dr Jan Irvine *et al.*,³⁵ was made under licence from McMaster University, Hamilton, ON, Canada.

We would like to thank all the participants who took part in the study. We gratefully acknowledge the help of the following people.

The TOPPIC Collaborators Group.

Trial Steering Committee: Chris Probert, John Mansfield, Stuart Ralston, Ruth Slater, Craig Mowat and Steff Lewis.

Data Monitoring Committee: Stephen JW Evans, Huw Roddie and Helen Gillett.

Data Management Group: Jack Satsangi, Ian Arnott and Debbie Kerr.

Safety blood review clinicians: Jack Satsangi, Ian Arnott, Craig Mowat, Ashley Mowat, Aidan Cahill, Mhairi Collie, Jack Winter, Malcolm Smith, Aileen McKinley, Daniel Gaya, John Morris, John Todd, John Thomson and Graham Naismith.

Recruiting centres (collaborating doctors and nurse; the principal investigator is listed first):

- Western General Hospital, Edinburgh – Dr Ian Arnott, Debbie Kerr and Gail Scott
- Ninewells Hospital, Dundee – Dr Craig Mowat and Shirley Cleary
- Aberdeen Royal Infirmary, Aberdeen – Dr Malcolm Smith and Jenny Robb
- Glasgow Royal Infirmary, Glasgow – Dr Daniel Gaya and Joanna Munro
- Stobhill Hospital, Glasgow – Dr Aidan Cahill and Liz Lightbody
- Raigmore Hospital, Inverness – Dr Lindsay Potts and Ian Shread
- Queen Elizabeth Hospital, Birmingham – Dr Jason Goh, Sian Davis and Vishy Veerana
- Bristol Royal Infirmary, Bristol – Dr Tom Creed, Jane Bowles and Andrew Parker
- University Hospital Coventry, Coventry – Dr Chuka Nwokolo and Emily Archer
- County Durham and Darlington Memorial Hospitals, Durham and Darlington – Dr Anjan Dhar and Claire Shaw
- Royal Devon and Exeter Hospital, Exeter – Dr Tariq Ahmad, Dr Kenji So, Dr Ollie Waters and Suzie Marriott
- Hull Royal Infirmary, Hull – Dr Shaji Sebastian and Bronwen Williams
- Leeds General Infirmary, Leeds – Dr John Hamlin, Dr Alex Ford and Doris Quartey
- Royal Liverpool University Hospital, Liverpool – Dr Shreedhar Subramanian, Dr Keith Leiper and Kate Martin
- Manchester Royal Infirmary, Manchester – Dr Scott Levison, Dr Simon Campbell and Jane Taylor
- University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent – Dr Sandip Sen and Sue Gallagher
- Nottingham University Hospital, Nottingham – Professor Chris Hawkey, Jenny Salmon and Michelle Mieszek
- Rotherham NHS Foundation Trust Hospital, Rotherham – Dr Mohamed Yousif, Meredyth Harris and Rachel Walker
- Royal Free Hospital, London – Dr Charles Murray and Orla Brady
- Salford Royal Hospital, Salford – Dr Simon Lal and Anne Keen
- Barts Health NHS Trust St Bartholomew's Hospital, London – Dr James Lindsay, Louise Langmead, Jacqueline Nichols and Abu Karim
- St Mark's Hospital, Harrow – Dr Naila Arebi and Sherrill Tripoli
- Abertawe Bro Morgannwg University Health Board Singleton Hospital, Swansea – Dr Linzi Thomas and Caradog Thomas

- Torbay Hospital, Torquay – Dr Cathryn Edwards and Jan Palmer
- University College Hospital, London – Dr Stuart Bloom, Belinda Theis, Elen Witness and Roman Jastrub.

Edinburgh Clinical Trials Unit: Audrey Duncan, Garry Milne, Allan Walker, Lynsey Milne, Samantha Thomas, Ashma Krishnan, Debbie Kerr, Gail Scott and Helen Watters.

Academic and Clinical Central Office for Research & Development: Marise Bucukoglu, Anne Langston, Ray French and Vikki Young.

Wellcome Trust Clinical Trial Facility Genetics Core: Lee Murphy and Mark Blandford.

Viapath laboratory, Guy's and St Thomas' Hospital: Tony Marinaki.

Histopathology laboratory: Ann Jarvie and Susan A Walker.

Pathology laboratory: David Worrall.

Cedars Sinai: Dermot McGovern and Carol J Landers.

We also wish to thank the MRC and National Institute for Health Research (NIHR)'s EME programme, the Scottish Government's Chief Scientist Office and the NIHR National Portfolio.

Contributions of authors

Professor Jack Satsangi (Consultant in Gastroenterology, Division of Gastroenterology) was the chief investigator. He devised the study, was involved in the design and conduct of research, and was a member of the trial development group, project management group and the TSC. He was also involved in the development and refinement of the protocol, the conduct of the research interpretation and the reporting of results, and he revised the manuscript for important intellectual content.

Dr Nicholas A Kennedy (Consultant Gastroenterologist and Honorary Clinical Senior Lecturer) was a research fellow at the Edinburgh site. He was involved in the conduct of the research interpretation and the reporting of results, including the analysis of the predictive data and samples, and he revised the manuscript for important intellectual content.

Dr Craig Mowat (Consultant in Gastroenterology, Gastroenterology Department) was the principal investigator at the Dundee site. He was involved in the design and conduct of research, and was a member of the trial development group and the TSC. He was also involved in the development and refinement of the protocol, the conduct of the research interpretation and the reporting of results, and he revised the manuscript for important intellectual content.

Dr Ian Arnott (Consultant in Gastroenterology, Division of Gastroenterology) was the principal investigator at the Edinburgh site. He was involved in the design and conduct of research, and was a member of the trial development group, project management group and the TSC. He was also involved in the development and refinement of the protocol, the conduct of the research interpretation and the reporting of results, and he revised the manuscript for important intellectual content.

Mrs Catriona Keerie (Statistician) was the study statistician who wrote the statistical analysis plan and undertook the end-of-study analysis. She prepared the final study statistical report and was involved in the interpretation and reporting of results, and the drafting and revision of this manuscript for important intellectual content.

Dr Steff Lewis (Reader in Medical Statistics) was the lead study statistician and was involved in the design and conduct of research, the TSC, the interpretation and reporting of results, and the drafting and revision of the manuscript for important intellectual content.

Dr Holly Ennis (Trial Manager from August 2013) was involved in the day-to-day trial management, data management and was a member of the TMG.

Publication

Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, *et al.* Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2016;**1**:273–82.

Data sharing statement

All available data can be obtained from the corresponding author via the ECTU in accordance with the ECTU Data Sharing Policy. This policy is currently under development, but will be based on the MRC Hubs for Trials Methodology Research '*Good Practice Principles for Sharing Individual Participant Data from Publicly Funded Clinical Trials*', published in April 2015.³⁶

References

1. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. *Aliment Pharmacol Ther* 2000;**14**:1553–9. <https://doi.org/10.1046/j.1365-2036.2000.00886.x>
2. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. *Cochrane Database Syst Rev* 2000;**2**:CD000545.
3. Gordon M, Taylor K, Akobeng AK, Thomas AG. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. *Cochrane Database Syst Rev* 2014;**8**:CD010233. <https://doi.org/10.1002/14651858.CD010233.pub2>
4. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. *Cochrane Database Syst Rev* 2000;**2**:CD000067.
5. Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. *Ann Surg* 1991;**214**:230–8. <https://doi.org/10.1097/00000658-199109000-00006>
6. Van Assche G, Rutgeerts P. Medical management of postoperative recurrence in Crohn's disease. *Gastroenterol Clin North Am* 2004;**33**:347–60, x. <https://doi.org/10.1016/j.gtc.2004.02.012>
7. Post S, Herfarth C, Böhm E, Timmermanns G, Schumacher H, Schürmann G, Golling M. The impact of disease pattern, surgical management, and individual surgeons on the risk for relaparotomy for recurrent Crohn's disease. *Ann Surg* 1996;**223**:253–60. <https://doi.org/10.1097/00000658-199603000-00005>
8. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, *et al.* Guidelines for the management of inflammatory bowel disease in adults. *Gut* 2011;**60**:571–607. <https://doi.org/10.1136/gut.2010.224154>
9. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. *Gastroenterol* 2015;**148**:64–76. <https://doi.org/10.1053/j.gastro.2014.09.031>
10. Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J. Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance – progress and prospects. *Aliment Pharmacol Ther* 2014;**39**:1253–65. <https://doi.org/10.1111/apt.12743>
11. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, *et al.* Infliximab prevents Crohn's disease recurrence after ileal resection. *Gastroenterology* 2009;**136**:441–50.e1. <https://doi.org/10.1053/j.gastro.2008.10.051>
12. Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, *et al.* Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. *Inflamm Bowel Dis* 2012;**18**:1617–23. <https://doi.org/10.1002/ibd.21928>
13. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, *et al.* Crohn's disease management after intestinal resection: a randomised trial. *Lancet* 2015;**385**:1406–17. [https://doi.org/10.1016/S0140-6736\(14\)61908-5](https://doi.org/10.1016/S0140-6736(14)61908-5)
14. Cuillerier E, Lémann M, Bouhnik Y, Allez M, Rambaud JC, Modigliani R. Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. *Eur J Gastroenterol Hepatol* 2001;**13**:1291–6. <https://doi.org/10.1097/00042737-200111000-00005>

15. Domènech E, Scala L, Bernal I, García-Planella E, Casalots A, Piñol M, *et al.* [Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study.] *Gastroenterol Hepatol* 2004;**27**:563–7. [https://doi.org/10.1016/S0210-5705\(03\)70533-0](https://doi.org/10.1016/S0210-5705(03)70533-0)
16. Nos P, Hinojosa J, Aguilera V, Molés JR, Pastor M, Ponce J, Berenguer J. [Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease.] *Gastroenterol Hepatol* 2000;**23**:374–8.
17. Korelitz B, Hanauer S, Rutgeerts P, Present D, Peppercorn M. Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease. A two-year multicenter trial. *Gastroenterology* 1998;**114**:A1011. [https://doi.org/10.1016/S0016-5085\(98\)84115-2](https://doi.org/10.1016/S0016-5085(98)84115-2)
18. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. *Gastroenterology* 2004;**127**:723–9. <https://doi.org/10.1053/j.gastro.2004.06.002>
19. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, *et al.* Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. *Gastroenterology* 2004;**127**:730–40. <https://doi.org/10.1053/j.gastro.2004.06.051>
20. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, *et al.* The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. *J Crohns Colitis* 2010;**4**:28–62. <https://doi.org/10.1016/j.crohns.2009.12.002>
21. Coelho J, Beaugerie L, Colombel JF, Hébuterne X, Lerebours E, Lémann M, *et al.* Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. *Gut* 2011;**60**:198–203. <https://doi.org/10.1136/gut.2010.222893>
22. Casanova MJ, Chaparro M, Domènech E, Barreiro-de Acosta M, Bermejo F, Iglesias E, *et al.* Safety of thiopurines and anti-TNF- α drugs during pregnancy in patients with inflammatory bowel disease. *Am J Gastroenterol* 2013;**108**:433–40. <https://doi.org/10.1038/ajg.2012.430>
23. Ban L, Tata LJ, Fiaschi L, Card T. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. *Gastroenterology* 2014;**146**:76–84. <https://doi.org/10.1053/j.gastro.2013.09.061>
24. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 1989;**170**:2–6. <https://doi.org/10.3109/00365528909091339>
25. Best WR, Beckett JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976;**70**:439–44.
26. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. *Gut* 1984;**25**:665–72. <https://doi.org/10.1136/gut.25.6.665>
27. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Études Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). *Gut* 1989;**30**:983–9. <https://doi.org/10.1136/gut.30.7.983>
28. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. *Gastroenterology* 1989;**96**:804–10. [https://doi.org/10.1016/S0016-5085\(89\)80080-0](https://doi.org/10.1016/S0016-5085(89)80080-0)
29. Freier A, Karlton P, Kocher P. *The Secure Sockets Layer (SSL) Protocol Version 3.0*. 2011. URL: <https://tools.ietf.org/html/rfc6101> (accessed 6 June 2017).

30. Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, *et al.* Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2016;**1**:273–82. [https://doi.org/10.1016/S2468-1253\(16\)30078-4](https://doi.org/10.1016/S2468-1253(16)30078-4)
31. National Institute for Health Research. *Efficacy and Mechanism Evaluation*. URL: www.nihr.ac.uk/funding-and-support/funding-for-research-studies/funding-programmes/efficacy-and-mechanism-evaluation/ (accessed 6 June 2017).
32. Yamamoto T, Keighley MR. Smoking and disease recurrence after operation for Crohn's disease. *Br J Surg* 2000;**87**:398–404. <https://doi.org/10.1046/j.1365-2168.2000.01443.x>
33. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. *Int J Colorectal Dis* 2008;**23**:1213–21. <https://doi.org/10.1007/s00384-008-0542-9>
34. D'Haens GR, Vermeire S, Van Assche G. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. *Gastroenterol* 2008;**135**:1123–9. <https://doi.org/10.1053/j.gastro.2008.07.010>
35. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 1999;**28**:S23–7. <http://dx.doi.org/10.1097/00005176-199904001-00003>
36. Smith CT, Hopkins C, Sydes M, Woolfall K, Clarke M, Murray G, *et al.* *Good Practice Principles for Sharing Individual Participant Data from Publicly Funded Clinical Trials*. 2015. URL: www.methodologyhubs.mrc.ac.uk/pdf/Datasharingguidance2015.pdf (accessed 4 September 2017).

A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and depth.

**EME
HS&DR
HTA
PGfAR
PHR**

Part of the NIHR Journals Library
www.journalslibrary.nihr.ac.uk

This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health

Published by the NIHR Journals Library